<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title-group>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
</journal-title-group>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2025.1639005</article-id>
<article-version article-version-type="Version of Record" vocab="NISO-RP-8-2008"/>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Research</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>An integrative model of pro- and anti-inflammatory signaling pathways in macrophage differentiation: the role of NF-<italic>&#x3ba;</italic>B and CREB</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Mart&#xed;nez-M&#xe9;ndez</surname><given-names>David</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/523329/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Aguilar-Elguea</surname><given-names>Ilean Z.</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Castel&#xe1;n-Pacheco</surname><given-names>Lilian S.</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Jim&#xe9;nez-Alvarez</surname><given-names>Luis Armando</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/465039/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Cruz-Lagunas</surname><given-names>Alfredo</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/2042821/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Z&#xfa;&#xf1;iga</surname><given-names>Joaqu&#xed;n</given-names></name>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/444932/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
</contrib>
<contrib contrib-type="author">
<name><surname>Villarreal</surname><given-names>Carlos</given-names></name>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/54500/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Huerta</surname><given-names>Leonor</given-names></name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>*</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/494296/overview"/>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project-administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x2013; review &amp; editing</role>
<role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x2013; original draft</role>
</contrib>
</contrib-group>
<aff id="aff1"><label>1</label><institution>Instituto de Investigaciones Biom&#xe9;dicas, Departamento de Inmunolog&#xed;a, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico</institution>, <city>Mexico City</city>,&#xa0;<country country="mx">Mexico</country></aff>
<aff id="aff2"><label>2</label><institution>Instituto de F&#xed;sica, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico</institution>, <city>Mexico City</city>,&#xa0;<country country="mx">Mexico</country></aff>
<aff id="aff3"><label>3</label><institution>Instituto Nacional de Enfermedades Respiratorias Ismael Cos&#xed;o Villegas, Secretar&#xed;a de Salud, Tecnol&#xf3;gico de Monterrey, Escuela de Medicina y Ciencias de la Salud, CCM</institution>, <city>Mexico City</city>,&#xa0;<country country="mx">Mexico</country></aff>
<author-notes>
<corresp id="c001"><label>*</label>Correspondence: Leonor Huerta, <email xlink:href="mailto:leonorhh@iibiomedicas.unam.mx">leonorhh@iibiomedicas.unam.mx</email>; David Mart&#xed;nez-M&#xe9;ndez, <email xlink:href="mailto:davidmartinezmendez@gmail.com">davidmartinezmendez@gmail.com</email></corresp>
</author-notes>
<pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-01-02">
<day>02</day>
<month>01</month>
<year>2026</year>
</pub-date>
<pub-date publication-format="electronic" date-type="collection">
<year>2025</year>
</pub-date>
<volume>16</volume>
<elocation-id>1639005</elocation-id>
<history>
<date date-type="received">
<day>01</day>
<month>06</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>17</day>
<month>11</month>
<year>2025</year>
</date>
<date date-type="rev-recd">
<day>11</day>
<month>09</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2026 Mart&#xed;nez-M&#xe9;ndez, Aguilar-Elguea, Castel&#xe1;n-Pacheco, Jim&#xe9;nez-Alvarez, Cruz-Lagunas, Z&#xfa;&#xf1;iga, Villarreal and Huerta.</copyright-statement>
<copyright-year>2026</copyright-year>
<copyright-holder>Mart&#xed;nez-M&#xe9;ndez, Aguilar-Elguea, Castel&#xe1;n-Pacheco, Jim&#xe9;nez-Alvarez, Cruz-Lagunas, Z&#xfa;&#xf1;iga, Villarreal and Huerta</copyright-holder>
<license>
<ali:license_ref start_date="2026-01-02">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
<license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Monocytes are essential players of the innate immune response and adapt their functional states in response to different antigenic and cytokine environments. Integrating the complexity of monocyte intracellular signaling into a mathematical model can support the understanding of dynamic transitions that are crucial for immune regulation.</p>
</sec>
<sec>
<title>Objective</title>
<p>To formulate a comprehensive mathematical model of monocyte activation, differentiation, and metabolic adaptation dynamics in response to a variety of stimulus and cytokine microenvironment.</p>
</sec>
<sec>
<title>Methodology</title>
<p>The model comprises a 128-node complex regulatory network based on known components of monocyte activation signal pathways. Node interactions are described by continuous fuzzy logic rules, and includes signaling events induced by LPS, activating IgG immune complexes, ssRNA, and the IFN-<italic>&#x3b3;</italic>, IL-4 and IL-10 cytokines. Autocrine feedback loops for IL-10 and TNF-<italic>&#x3b1;</italic>, and a metabolism subnetwork were included. The network was analyzed by a set of ordinary differential equations (ODEs) system. The system outputs describe the dynamics of cell metabolic activity, activation of transcription factors, cytokine production and phagocytosis. An interactive program was developed as a tool to test the dynamical expression of the monocyte features under different initial conditions (see the <ext-link ext-link-type="uri" xlink:href="https://grci.mx/modelos.html">https://grci.mx/modelos.html</ext-link> website).</p>
</sec>
<sec>
<title>Results</title>
<p>The model captures the dynamics of the main events rendering stable states corresponding to the M1, M2, M2b and M2c macrophage profiles. Results are compatible with the predominance of glycolysis in the M1 and M2b, and oxidative phosphorylation in the M2a and M2c responses. The model shows the convergence to the activation of the NF-<italic>&#x3ba;</italic>B transcription factor in the pro-inflammatory response, while anti-inflammatory profiles are related to the induction of CREB1, a NF-<italic>&#x3ba;</italic>B inhibitor and promoter of IL-10 synthesis. Modelling supports a fundamental role of the Akt isoforms Akt1 and Akt3 in the induction of the activity the CREB1 inhibitor GSK3<italic>&#x3b2;</italic> upon IFN-<italic>&#x3b3;</italic> signaling, so enabling the pro-inflammatory response. The anti-NF-<italic>&#x3ba;</italic>B activity of IL-4 signaling can turn the response into an M2 profile. The model predicts the relative levels of IFN-<italic>&#x3b3;</italic> necessary to sustain the inflammatory response. Stochastic modelling proved the robustness of the macrophage differentiation process.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>The complex network approach presented here integrates diverse cytokine and antigenic signaling leading to macrophage responses. It supports a mechanism for the IFN-<italic>&#x3b3;</italic> mediated inhibition of CREB in the balance between pro-inflammatory and anti-inflammatory signals.</p>
</sec>
</abstract>
<kwd-group>
<kwd>inflammation</kwd>
<kwd>macrophage differentiation</kwd>
<kwd>anti-inflammatory cytokines</kwd>
<kwd>CREB</kwd>
<kwd>biological network</kwd>
<kwd>LPS</kwd>
<kwd>IFN-&#x3b3;</kwd>
<kwd>mathematical model</kwd>
</kwd-group>
<funding-group>
<award-group id="gs1">
<funding-source id="sp1">
<institution-wrap>
<institution>Direccion General de Asuntos del Personal Academico, Universidad Nacional Autonoma de Mexico</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100006087</institution-id>
</institution-wrap>
</funding-source>
<award-id rid="sp1">IG200623</award-id>
</award-group>
<award-group id="gs2">
<funding-source id="sp2">
<institution-wrap>
<institution>Instituto de Investigaciones Biomedicas, Universidad Nacional Autonoma de Mexico</institution>
<institution-id institution-id-type="doi" vocab="open-funder-registry" vocab-identifier="10.13039/open_funder_registry">10.13039/501100020704</institution-id>
</institution-wrap>
</funding-source>
</award-group>
<funding-statement>The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by Programa de Apoyo a Proyectos de Investigaci&#xf3;n e Innovaci&#xf3;n Tecnol&#xf3;gica of the Universidad Nacional Aut&#xf3;noma de M&#xe9;xico (grant number IG200623 to LH and CV), Consejo Nacional de Ciencias, Humanidades y Tecnolog&#xed;a de M&#xe9;xico (grant CBF23-24 348 to LH), and Instituto de Investigaciones Biom&#xe9;dicas of UNAM. DM-M received a postdoctoral fellowship from Secretar&#xed;a de Ciencia, Humanidades, Tecnolog&#xed;a e Innovaci&#xf3;n of M&#xe9;xico (CVU number 555239 to DM-M).</funding-statement>
</funding-group>
<counts>
<fig-count count="10"/>
<table-count count="3"/>
<equation-count count="7"/>
<ref-count count="64"/>
<page-count count="19"/>
<word-count count="8706"/>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Systems Immunology</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<label>1</label>
<title>Introduction</title>
<p>Monocytes are involved in pathogen clearance, inflammation, tissue repair, and immune regulation. They pose a variety of receptors for the recognition, internalization, and processing of foreign antigens, along with cytokine receptors that contribute to modulation of adaptive immunity and tissue homeostasis (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). Macrophages differentiate into the M1 phenotype, which is pro-inflammatory and effective in removing pathogens, and three different kind of M2 phenotypes involved in tissue repair and immune regulation. Prototypic M1 macrophages are induced by the combination of lipopolysaccharides (LPS) and interferon gamma (IFN-<italic>&#x3b3;</italic>), and produce cytokines such as tumor necrosis factor-<italic>&#x3b1;</italic> (TNF-<italic>&#x3b1;</italic>) and interleukine-12 (IL-12). In contrast, M2 macrophages are induced by signals such as interleukine-4 (IL-4) and interleukine-10 (IL-10), which promote tissue repair functions and down-regulate pro-inflammatory responses, preventing excessive tissue damage (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). The M2a phenotype develops in the presence of IL-4, M2b requires IL-1-<italic>&#x3b2;</italic> and additional stimulation, while M2c depends on IL-10 or TGF-<italic>&#x3b2;</italic> (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). Metabolic adaptability associated to M1- or M2-type responses is driven by signaling pathways related to mTOR and AMPK. (<xref ref-type="bibr" rid="B7">7</xref>), with glycolysis and oxidative phosphorylation (OXPHOS) modulated in response to energy demands and conditions such as hypoxia and nutrient-deprived environments, commonly encountered in inflamed tissues (<xref ref-type="bibr" rid="B8">8</xref>). Thus, macrophage differentiation into alternative phenotypes is determined by the interaction between signals from receptor activation and the cytokine microenvironment. (<xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>The inherent complexity of these highly intertwined processes makes it very difficult to understand emergent behaviors, such as phenotype differentiation and immune cell decisions, using only intuition (<xref ref-type="bibr" rid="B10">10</xref>). Mathematical analysis based on complex regulatory networks provide an operating way to represent biological circuits composed of numerous elements that contain signaling cascades or switching modules; this approach may yield meaningful qualitative information on the basic topology of relations that determine alternative cell fates, so that it can be used for network analysis without requiring explicit values of biological parameters (<xref ref-type="bibr" rid="B11">11</xref>&#x2013;<xref ref-type="bibr" rid="B14">14</xref>). Here, we used this tool to explore how monocytes respond to signals in different microenvironments of cytokines, offering an integrated view of monocyte function. Early studies have been performed by Palma et&#xa0;al. to characterize the logical relationships among genes driving macrophage polarization to the M1 and M2 phenotypes (<xref ref-type="bibr" rid="B9">9</xref>).</p>
<p>In this work we put forth a network including signaling from Toll-like receptors (TLR) which recognize pathogen-associated molecular patterns (PAMPs), such as LPS and nucleic acids, detecting bacterial, viral, or fungal infections. The range of TLR includes TLR2 to TLR4, and TLR7 to TLR9, each responding to specific pathogen structures and triggering downstream signaling pathways that activate nuclear factor-kappa B (RelA(p65)/p50 complex)), mitogen-activated protein kinases (MAPKs), and interferon regulatory factors (IRFs) (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Notably, the cAMP responsive element binding protein (CREB1, or CREB11), which has been considered a pro-inflammatory co-regulator of NF-<italic>&#x3ba;</italic>B and AP-1 (c-Fos and c-Jun) (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>), is also known to play a central role in the inhibition of NF-<italic>&#x3ba;</italic>B and the production of the anti-inflammatory cytokine IL-10. The activity of the CREB1 inhibitor GSK3<italic>&#x3b2;</italic>, which is constitutively expressed in nonactivated monocytes (<xref ref-type="bibr" rid="B19">19</xref>), was introduced in the network to analyze its role in the modulation of the inflammatory response.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<label>2</label>
<title>Materials and methods</title>
<sec id="s2_1">
<label>2.1</label>
<title>Regulatory network defined by logical interaction rules</title>
<p>The mathematical methodology employed in this work is summarized in <xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>. An overall assumption is that activation, differentiation and effector processes in cells comply with logical rules comprising a regulatory network of node interactions, underlying a (metaphorical) epigenetic landscape (<xref ref-type="bibr" rid="B20">20</xref>). <xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref> displays the regulatory network for macrophage differentiation put forth in this work. It includes 128 components that incorporate current experimental evidence of the molecular interactions involved in the differentiation of the macrophage phenotypes M1, M2a, M2b, and M2c. The network consists of inputs (environmental stimulating agents) and nodes (representing receptors, enzymes, second messengers, transcription factors, genes, etc.) linked through activating or inhibitory interactions.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Flux diagram of the mathematical steps leading to the network continuous modelling of macrophage differentiation. <bold>(A)</bold> Epigenetic landscape showing stable states <bold>(Naive, Activated, M1, M2a, M2b, and M2c)</bold> and including hybrid phenotypes. <bold>(B)</bold> Diagram of intracellular signaling as node interactions. <bold>(C)</bold> Discrete dynamical evolution of a network described by Boolean logical rules. <bold>(D)</bold> Conversion from Boolean to fuzzy rules. <bold>(E)</bold> Graph of the truth value function with different node expression rates (beta). <bold>(F)</bold> Deterministic dynamical evolution showing node activity levels over time. <bold>(G)</bold> Robustness analysis can be performed by introducing stochastic perturbations in the network dynamics and calculating differentiation efficiency.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1639005-g001.tif">
<alt-text content-type="machine-generated">Illustration depicting a process of dynamical evolution through different network models. (A) Shows an epigenetic landscape with states labeled “Naive,” “Activated,” “M1,” “M2b,” “M2a,” and “M2c.” (B) Illustrates a regulatory network diagram with nodes and arrows. (C) Describes Boolean networks with a grid and formula for discrete dynamical evolution. (D) Details fuzzy networks with conversion rules. (E) Displays a truth value function graph with different beta values. (F) and (G) Present deterministic and stochastic dynamical evolution, each with graphs showing activity levels over time.</alt-text>
</graphic></fig>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Flow chart illustrating biological signaling pathways, categorized by function using color-coded boxes. Key elements include extracellular stimuli, receptors, extracellular and secreted cytokines, transcription factors, and metabolic processes. Arrows indicate positive (black) and negative (red) interactions. Particular interactions can be visualized in the interactive figure MONOCYTE NET.graphml in the <ext-link ext-link-type="uri" xlink:href="https://grci.mx"><italic>https://grci.mx</italic></ext-link> website. Subnetworks for NF-<italic>&#x3ba;</italic>B, CREB1, AMPK, IL-4 and IL-10 are shown in <xref ref-type="fig" rid="f3"><bold>Figures&#xa0;3</bold></xref>, <xref ref-type="fig" rid="f4"><bold>4</bold></xref>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1639005-g002.tif">
<alt-text content-type="machine-generated">Flowchart illustrating biological signaling pathways, categorized by function using color-coded boxes. Key elements include extracellular stimuli, receptors, cytokines, transcription factors, and metabolic processes depicted in various colors. Arrows indicate interactions.</alt-text>
</graphic></fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p><bold>(A)</bold> Interaction subnetworks of NF-&#x3ba;B, CREB1, and AMPK. <bold>(A)</bold> Stimulatory and inhibitory pathways converge on NF&#x3ba;b activity. NF&#x3ba;b activation leads to secretion of cytokines and activation of the glycolysis-inducer mTORC1. <bold>(B)</bold> CREB1 is activated by TNF&#x3b1;R and cytoplasmic ssRNA and dsRNA via p38; IFN-&#x3b3;-driven inhibition of Akt1 and Akt3 allows GSK3&#x3b2; to inhibit CREB, leading to NF-&#x3ba;B activation. <bold>(C)</bold> AMPK senses the AMP/ATP ratio and have a negative feedback interaction with mTORC1, defining a switch between oxidative OXPHOS and glycolysis.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1639005-g003.tif">
<alt-text content-type="machine-generated">Diagram depicting signalling interactions with sections labeled A, B, and C. Section A includes proteins like NF-kB, TNFa, and mTOR. Section B involves TLR pathways and associated proteins like CREB1 and MyD88. Section C features AMPK and mTORC pathways connected with metabolic processes like glycolysis and OXPHOS. Molecular interactions are illustrated with arrows.</alt-text>
</graphic></fig>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Subnetworks for the IL-4 and IL-10 immunomodulatory effect. Signaling from IL-4 <bold>(A)</bold> and IL-10 <bold>(B)</bold> receptors ((IL-4R&#x3b1;) and IL-10R, respectively) leads to inhibition of NFkB, production of IL-10 and activation of AMPK. AMPK directs the macrophage metabolism towards oxidative phosphorylation.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1639005-g004.tif">
<alt-text content-type="machine-generated">Diagrams for the IL-4 and IL-10 immunomodulatory effects. A) IL-4 infuences a network involving mTORC2, LKB1, AMPK, and others leading to production of  IL-10 and IL-12. B) IL-10 affects a related network with LKB1, STAT proteins, and NF-kB, also leading to IL-10 and IL-12 production. Various proteins and interactions are indicated by colored boxes and arrows, detailing complex signaling pathways.</alt-text>
</graphic></fig>
<p>In a first level, the network interactions are described by Boolean rules that allow to set up the network architecture, including feedback and switching modules. In the Boolean scheme, logic rules are defined by dichotomous variables with truth values, 0 (unexpressed), or 1 (expressed), and the network dynamics is described in terms of discrete-time mappings whose steady states (attractors) define cell phenotypes. A Boolean approach is fundamental for building the set of regulatory interactions; however, this procedure may be insufficient to account for the complex phenomenology observed in specific experimental studies. A more suitable modelling of biological systems may be achieved by introducing a continuous logical analysis (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). In this approach, the expression levels and concentrations of the signaling elements can acquire any value within a continuous range limited only by functionality constraints and concomitant continuous dynamics. Then, we extended our initial analysis to consider a regulatory network characterized by Fuzzy Logic, aimed to provide formal foundation to logical inferences involving uncertain or vague reasoning and has found applications in physical, control, biomedical, and linguistic sciences (<xref ref-type="bibr" rid="B23">23</xref>). In this approach, node interactions are described by continuous-valued logical propositions where the expression values of the variables, <italic>q<sub>i</sub></italic>, can be any real number ranging from completely false, 0, to totally true, 1 (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B14">14</xref>, <xref ref-type="bibr" rid="B24">24</xref>). The corresponding fuzzy interaction rules may be straightforwardly derived from their Boolean counterparts by replacing ordinary logic connectors by algebraic expressions, as shown in <xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>. The kind of approach has been previously employed by some of the present authors to describe differentiation and plasticity processes in floral organs (<xref ref-type="bibr" rid="B13">13</xref>), pancreatic beta cells (<xref ref-type="bibr" rid="B25">25</xref>), and CD4 T-cells (<xref ref-type="bibr" rid="B26">26</xref>&#x2013;<xref ref-type="bibr" rid="B28">28</xref>).</p>
<p>To proceed, we denote the expression levels of the network agent <italic>i</italic> at a time <italic>t</italic> by a continuous variable <italic>q<sub>i</sub></italic>(<italic>t</italic>), with 0 &#x2264; <italic>q<sub>i</sub></italic> &#x2264; 1. The network dynamics is then described by a set of ordinary differential equations (ODEs):</p>
<disp-formula id="eq1"><label>(1)</label>
<mml:math display="block" id="M1"><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>q</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mi>&#x3bc;</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mo>&#x2026;</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3b1;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math>
</disp-formula>
<p>Here, the input <inline-formula>
<mml:math display="inline" id="im1"><mml:mrow><mml:mi>&#x3bc;</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mtext>exp</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mo>&#x2212;</mml:mo><mml:mi>&#x3b2;</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mo>&#x2026;</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3b8;</mml:mi><mml:mrow><mml:mi>t</mml:mi><mml:mi>h</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> is a sigmoid function representing the truth value of the fuzzy interaction rule <italic>w<sub>i</sub></italic> with respect to a threshold <italic>&#x3b8;<sub>th</sub></italic>, and <italic>&#x3b2;</italic> is a saturation rate. The second term yields an interaction decay at a rate <inline-formula>
<mml:math display="inline" id="im2"><mml:mrow><mml:msub><mml:mi>&#x3b1;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:msub><mml:mi>&#x3c4;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, where <italic>&#x3c4;<sub>i</sub></italic> is a characteristic expression time. In this work, we assume <italic>&#x3b2;</italic> = 10, <italic>&#x3b8;<sub>th</sub></italic> = 1<italic>/</italic>2, and <italic>&#x3b1;<sub>i</sub></italic> = 1. The differentiation dynamics induced by any considered cell microenvironment can be simulated by solving the ODE system (1) for a fixed set of initial conditions {<italic>q<sub>i</sub></italic>(0)}. Solutions exhibit a long-time steady behavior, <inline-formula>
<mml:math display="inline" id="im3"><mml:mrow><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mi>T</mml:mi><mml:mo>&#x226b;</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, giving rise to a set of steady-state solutions <inline-formula>
<mml:math display="inline" id="im4"><mml:mrow><mml:mo>{</mml:mo><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mo>}</mml:mo></mml:mrow></mml:math></inline-formula>, as it will be shown in Results. In the simulations reported here, <italic>T</italic> = 30 is time long-enough long time long-enough. Alternatively, the set of steady-state solutions <inline-formula>
<mml:math display="inline" id="im5"><mml:mrow><mml:mo>{</mml:mo><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msubsup><mml:mo>}</mml:mo></mml:mrow></mml:math></inline-formula>, may be derived from the condition <italic>dq<sub>i</sub>/dt</italic> = 0, yielding</p>
<disp-formula id="eq2">
<mml:math display="block" id="M2"><mml:mrow><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:msub><mml:mi>&#x3b1;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>&#xa0;</mml:mo><mml:mi>&#x3bc;</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>q</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mo>&#x2026;</mml:mo><mml:mo>,</mml:mo><mml:msubsup><mml:mi>q</mml:mi><mml:mi>n</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math>
</disp-formula>
<p>and we may identify <inline-formula>
<mml:math display="inline" id="im6"><mml:mrow><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mo>.</mml:mo></mml:mrow></mml:math></inline-formula> Accordingly, the steady-state expression level of any network&#x2019;s agent is determined by the truth value of its steady logical connections, modulated by its decay rate <italic>&#x3b1;<sub>i</sub></italic>. In the case <inline-formula>
<mml:math display="inline" id="im7"><mml:mrow><mml:msub><mml:mi>&#x3b1;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>&#x226b;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, then <inline-formula>
<mml:math display="inline" id="im8"><mml:mrow><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msubsup><mml:mo>&#x2248;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>.</p>
</sec>
<sec id="s2_2">
<label>2.2</label>
<title>Simulation setup, data analysis and visualization</title>
<p>Simulations of the regulatory network dynamics were performed using a Python code involving numerical solvers for the ODEs described above; specifically, the &#x2018;odeint&#x2018; function from the &#x2018;scipy&#x2018; library. This allowed the implementation of an interactive program <italic>Final monocyte network.ipynb</italic> that may be used as a tool in the <italic>Google Colab</italic> application to test the dynamical expression of the network components under different microenvironmental and initial conditions. In particular, the initial conditions defining an unstimulated monocyte, {<italic>q<sub>k</sub></italic>(0)}, were set to zero for most input variables (except for AMPK and GSK3&#x3b2; activities, which were set to 1). Then, different stimulation conditions were applied, including LPS to activate TLR4, ssRNA to activate TLR7, IgG immune complexes to engage Fc<italic>&#x3b3;</italic> receptors, and combinations of these with cytokines (e.g. IL-4, IL-10). Each simulation was carried out over a predefined time interval, capturing the evolution of cell-produced cytokine levels, metabolic state, and transcription factor activities. The final steady states were analyzed to evaluate macrophage polarization markers under different stimulation conditions. Key variables, including cytokine expression, metabolic activity, and transcriptional factors dynamics, were plotted as time-series data to visualize the trajectories of monocyte activation and differentiation. Visualization was performed using the &#x2018;matplotlib&#x2018; library. Comparative analyses across conditions highlighted the influence of receptor activation and microenvironmental factors on the macrophage phenotype.</p>
<p>The results provided by the model have been validated against experimental data reported in the literature, ensuring consistency in cytokine profiles, metabolic shifts, and receptor-mediated differentiation. Sensitivity analyses were conducted to assess the robustness of the results to variations in parameter values. The Python code used for simulations is available upon request, ensuring reproducibility and transparency for future studies.</p>
</sec>
<sec id="s2_3">
<label>2.3</label>
<title>Robustness analysis</title>
<p>Robustness implies the capacity of a complex network to maintain its functionality subject to the action of topological or dynamical perturbations. Here, we assume that the network topology is already defined by selective forces, and we thus constrain our analysis to two different perturbation sources: i) the influence of randomly distributed initial values of the microenvironmental and cell variables on the differentiation stability. ii) the effect of noisy perturbations on the intrinsic differentiation dynamics, for fixed values of the initial microenvironment and cell variables.</p>
<sec id="s2_3_1">
<label>2.3.1</label>
<title>Effect of random distribution of initial values</title>
<p>To assess the stability of the system under parameter uncertainty we may consider a robustness index, <italic>R</italic>, that quantifies how much the model&#x2019;s steady-state solutions change when several parameters are jointly perturbed (<xref ref-type="bibr" rid="B29">29</xref>). By assuming that the baseline values of the set of system parameters of interest are described by the vector <inline-formula>
<mml:math display="inline" id="im9"><mml:mrow><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mo>&#x2026;</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>M</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, then the steady state solutions of <xref ref-type="disp-formula" rid="eq1">Equation 1</xref> associated to a parameter set <inline-formula>
<mml:math display="inline" id="im10"><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle></mml:math></inline-formula> and initial values <inline-formula>
<mml:math display="inline" id="im11"><mml:mrow><mml:msub><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>q</mml:mi></mml:mstyle><mml:mn>0</mml:mn></mml:msub></mml:mrow></mml:math></inline-formula>, can be denoted as <inline-formula>
<mml:math display="inline" id="im12"><mml:mrow><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>q</mml:mi></mml:mstyle><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msup><mml:mo>;</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:msub><mml:mi>&#x3b1;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. In this context, we may evaluate the stability of our original predictions due to influence of random parameter perturbations, <inline-formula>
<mml:math display="inline" id="im13"><mml:mrow><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mo>&#x2192;</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mo>+</mml:mo><mml:mi>&#x3b4;</mml:mi><mml:msup><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, within a range <inline-formula>
<mml:math display="inline" id="im14"><mml:mrow><mml:mo>&#x2225;</mml:mo><mml:mi>&#x3b4;</mml:mi><mml:msup><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>&#x2225;</mml:mo><mml:mo>&#x2264;</mml:mo><mml:msub><mml:mi>&#x3f5;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, where <italic>k</italic> indicates the number of a given simulation. Then, for a given choice of <inline-formula>
<mml:math display="inline" id="im15"><mml:mrow><mml:msub><mml:mi>&#x3f5;</mml:mi><mml:mi>R</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, the perturbed solutions are obtained from the ODE system:</p>
<disp-formula id="eq3">
<mml:math display="block" id="M3"><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>q</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mi>&#x3bc;</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>q</mml:mi></mml:mstyle><mml:mo>;</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mo>+</mml:mo><mml:mi>&#x3b4;</mml:mi><mml:msup><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3b1;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math>
</disp-formula>
<p>with steady state solutions, <inline-formula>
<mml:math display="inline" id="im16"><mml:mrow><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>&#x3b4;</mml:mi><mml:msup><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>&#x3bc;</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>q</mml:mi></mml:mstyle><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msup><mml:mo>;</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mo>+</mml:mo><mml:mi>&#x3b4;</mml:mi><mml:msup><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:msub><mml:mi>&#x3b1;</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>. By making the identification <inline-formula>
<mml:math display="inline" id="im17"><mml:mrow><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mrow><mml:mi>s</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup></mml:mrow></mml:math></inline-formula>, we may evaluate the deviation of the asymptotic perturbed solutions with respect to the original solution,</p>
<disp-formula>
<mml:math display="block" id="M4"><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo>&#x2225;</mml:mo><mml:msup><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>q</mml:mi></mml:mstyle><mml:mi>T</mml:mi></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mo>+</mml:mo><mml:mi>&#x3b4;</mml:mi><mml:msup><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x2212;</mml:mo><mml:msup><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>q</mml:mi></mml:mstyle><mml:mi>T</mml:mi></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x2225;</mml:mo><mml:mo stretchy="false">/</mml:mo><mml:mo>&#x2225;</mml:mo><mml:msup><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>q</mml:mi></mml:mstyle><mml:mi>T</mml:mi></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>p</mml:mi></mml:mstyle><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x2225;</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math>
</disp-formula>
<p>where <inline-formula>
<mml:math display="inline" id="im18"><mml:mrow><mml:mo>&#x2225;</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>q</mml:mi></mml:mstyle><mml:mo>&#x2225;</mml:mo><mml:mo>=</mml:mo><mml:msqrt><mml:mrow><mml:msubsup><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msubsup><mml:mi>q</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:msqrt></mml:mrow></mml:math></inline-formula> denotes the usual Euclidean norm. Then, the robustness index is determined by the expression.</p>
<disp-formula>
<mml:math display="block" id="M5"><mml:mrow><mml:mi>R</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x2212;</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">/</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:munderover><mml:mo>&#x2211;</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:msub><mml:mi>d</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math>
</disp-formula>
<p>where <italic>N</italic> is the total number of realizations of the perturbation procedure, and 0 &#x2264; <italic>R</italic> &#x2264; 1.</p>
<p>The robustness index was evaluated for random variations of initial levels of phenotype-inducing microenvironments: M1 (LPS and IFNG-<italic>&#x3b3;</italic>), M2a (IL-4), M2b (LPS and IL-1<italic>&#x3b2;</italic>) and M2c (IL-10), subject to three different perturbation levels, <italic>&#x3f5;<sub>R</sub></italic> = 0.1, 0.2, 0.3, with <italic>T</italic> = 30 time units and <italic>N</italic> = 500 iterations per considered scenario. Additionally, we performed a robustness test inducing perturbations only of the saturation response rate, <italic>&#x3b2;</italic>, an important parameter defining the rate at which the network elements can increase their activity.</p>
</sec>
<sec id="s2_3_2">
<label>2.3.2</label>
<title>Effect of noise on differentiation efficiency</title>
<p>We evaluate the differentiation efficiency, <inline-formula>
<mml:math display="inline" id="im19"><mml:mrow><mml:msub><mml:mi>&#x3f5;</mml:mi><mml:mi>D</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, defined as the fraction of cells reaching optimal expression levels (&#x223c; 1) of phenotype-specific transcription factors (and associated cytokines) when the dynamic variables of the system are perturbed by stochastic interactions (<xref ref-type="bibr" rid="B28">28</xref>). This parameter may take values in the range <inline-formula>
<mml:math display="inline" id="im20"><mml:mrow><mml:mn>0</mml:mn><mml:mo>&#x2264;</mml:mo><mml:msub><mml:mi>&#x3f5;</mml:mi><mml:mi>D</mml:mi></mml:msub><mml:mo>&#x2264;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>, with <inline-formula>
<mml:math display="inline" id="im21"><mml:mrow><mml:msub><mml:mi>&#x3f5;</mml:mi><mml:mi>D</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> corresponding to an idealized situation in absence of noise. For simplicity, in the following we the denote the expression level set {<italic>q<sub>i</sub></italic>} by a vector <bold>q</bold> = (<italic>q</italic><sub>1</sub><italic>, .., q<sub>n</sub></italic>). Noise perturbations are introduced in the description by introducing stochastic interactions <italic>&#x3be;<sub>i</sub></italic>(<italic>t</italic>) into the original ODE system (1):</p>
<disp-formula><label>(2)</label>
<mml:math display="block" id="M6"><mml:mrow><mml:mi>d</mml:mi><mml:msub><mml:mi>q</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">/</mml:mo><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mi>&#x3bc;</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mstyle mathvariant="bold" mathsize="normal"><mml:mi>q</mml:mi></mml:mstyle><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>&#x2212;</mml:mo><mml:msub><mml:mi>&#x3b1;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>q</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>&#x3be;</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math>
</disp-formula>
<p>Here, <italic>&#x3be;<sub>i</sub></italic>(<italic>t</italic>) is a random Gaussian variable, with null average &#x27e8;<italic>&#x3be;<sub>i</sub></italic>(<italic>t</italic>)&#x27e9; = 0, and a very short-time correlation &#x27e8;<italic>&#x3be;<sub>i</sub></italic>(<italic>t</italic>)<italic>&#x3be;<sub>i</sub></italic>(<italic>t' </italic>)&#x27e9;=2<italic>Q&#x3b4;</italic>(<italic>t</italic>&#x2013;<italic>t' </italic>), where <italic>Q</italic> is a measure of the noise intensity, while <italic>&#x3b4;</italic> is a Dirac-delta distribution centered at time <inline-formula>
<mml:math display="inline" id="im22"><mml:mrow><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mi>t</mml:mi><mml:mo>&#x2032;</mml:mo></mml:msup></mml:mrow></mml:math></inline-formula>. Using this methodology, we analyzed the monocyte differentiation efficiency by introducing different levels of noise, <italic>Q</italic>, into the dynamical <xref ref-type="disp-formula" rid="eq2">Equation 2</xref> and performed 1,000 iterations. Average and standard deviation were calculated in order to estimate <inline-formula>
<mml:math display="inline" id="im23"><mml:mrow><mml:msub><mml:mi>&#x3f5;</mml:mi><mml:mi>D</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> under each assayed condition.</p>
</sec>
</sec>
<sec id="s2_4">
<label>2.4</label>
<title>Network&#x2019;s modules</title>
<p>The network, displayed in <xref ref-type="fig" rid="f2"><bold>Figure&#xa0;2</bold></xref>, includes nodes and green or red arrows that represent activating or inhibitory node interactions. The specific exogenous inputs are listed in <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>, while the resulting Boolean interaction rules are presented in <xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref>. For a visual assessment of the built-in elements, the network is presented as interconnected modules, whose different colors denote specific functions: extracellular stimuli, TLR&#x2019;s, activating IgG immune complexes, cytokine receptors, downstream signals, metabolism, transcription factors, and secreted cytokines (output cytokines). Details of particular interactions can be visualized using the Yed software as <italic>MONOCYTE NET.graphml</italic> in the <ext-link ext-link-type="uri" xlink:href="https://grci.mx"><italic>https://grci.mx</italic></ext-link> web site.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Extracellular stimuli (inputs).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Input</th>
<th valign="middle" align="left">Notation</th>
<th valign="middle" align="left">Description</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Lipoprotein (TLR2 ligand)</td>
<td valign="middle" align="left">LP</td>
<td valign="middle" align="left">Exogenous lipoprotein stimulating TLR2 signaling.</td>
</tr>
<tr>
<td valign="middle" align="left">Double-Stranded RNA</td>
<td valign="middle" align="left">DSRNA</td>
<td valign="middle" align="left">Viral dsRNA acting as a TLR3 agonist.</td>
</tr>
<tr>
<td valign="middle" align="left">Single-Stranded RNA</td>
<td valign="middle" align="left">SSRNA</td>
<td valign="middle" align="left">Viral ssRNA acting as a TLR7/8 agonist.</td>
</tr>
<tr>
<td valign="middle" align="left">CpG DNA</td>
<td valign="middle" align="left">CPGDNA</td>
<td valign="middle" align="left">Unmethylated CpG motifs acting as a TLR9 agonist.</td>
</tr>
<tr>
<td valign="middle" align="left">Interferon Gamma</td>
<td valign="middle" align="left">IFNGE</td>
<td valign="middle" align="left">Cytokine input for IFN-<italic>&#x3b3;</italic> receptor activation.</td>
</tr>
<tr>
<td valign="middle" align="left">GM-CSF</td>
<td valign="middle" align="left">GMCSFE</td>
<td valign="middle" align="left">Cytokine that activates the CSF2 receptor (GM-CSF signaling).</td>
</tr>
<tr>
<td valign="middle" align="left">Interleukin-1 Beta</td>
<td valign="middle" align="left">IL1BE</td>
<td valign="middle" align="left">Pro-inflammatory cytokine input.</td>
</tr>
<tr>
<td valign="middle" align="left">Lipopolysaccharide Endotoxin</td>
<td valign="middle" align="left">LPSE</td>
<td valign="middle" align="left">LPS stimulus for TLR4 activation.</td>
</tr>
<tr>
<td valign="middle" align="left">Interleukin-4</td>
<td valign="middle" align="left">IL4E</td>
<td valign="middle" align="left">Cytokine promoting M2 (regulatory) polarization.</td>
</tr>
<tr>
<td valign="middle" align="left">Interleukin-10</td>
<td valign="middle" align="left">IL10E</td>
<td valign="middle" align="left">Anti-inflammatory cytokine input.</td>
</tr>
<tr>
<td valign="middle" align="left">Inactivated C3b</td>
<td valign="middle" align="left">IC3B</td>
<td valign="middle" align="left">Complement fragment contributing to opsonization.</td>
</tr>
<tr>
<td valign="middle" align="left">Immunoglobulin G</td>
<td valign="middle" align="left">IGGC</td>
<td valign="middle" align="left">IgG input for Fc<italic>&#x3b3;</italic> receptor (FCGR)</td>
</tr>
<tr>
<td valign="middle" align="left">Immunoglobulin A</td>
<td valign="middle" align="left">IGAC</td>
<td valign="middle" align="left">IgA immune complex influencing the activity of the Fc<italic>&#x3b1;</italic> receptor.</td>
</tr>
<tr>
<td valign="middle" align="left">Oxygen</td>
<td valign="middle" align="left">O2</td>
<td valign="middle" align="left">Extracellular oxygen concentration.</td>
</tr>
<tr>
<td valign="middle" align="left">Fatty Acids</td>
<td valign="middle" align="left">FA</td>
<td valign="middle" align="left">Availability of fatty acids for metabolism.</td>
</tr>
<tr>
<td valign="middle" align="left">Glucose</td>
<td valign="middle" align="left">GLC</td>
<td valign="middle" align="left">Glucose concentration in the extracellular environment.</td>
</tr>
<tr>
<td valign="middle" align="left">Cytosolic Double-Stranded RNA</td>
<td valign="middle" align="left">CITDSRNA</td>
<td valign="middle" align="left">Activator of the RIG-I pathway (dsRNA signal).</td>
</tr>
<tr>
<td valign="middle" align="left">Cytosolic Single-Stranded RNA</td>
<td valign="middle" align="left">CITSSRNA</td>
<td valign="middle" align="left">Activator of the RIG-I pathway (ssRNA signal).</td>
</tr>
<tr>
<td valign="middle" align="left">Tumor Necrosis Factor <italic>&#x3b1;</italic></td>
<td valign="middle" align="left">TNFA</td>
<td valign="middle" align="left">Pro-inflammatory cytokine input.</td>
</tr>
<tr>
<td valign="middle" align="left">Cellular Inhibitor of Apoptosis</td>
<td valign="middle" align="left">CIAP</td>
<td valign="middle" align="left">Regulator modulating TNF receptor downstream signaling</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Boolean rules*, **.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Standard nomenclature</th>
<th valign="middle" align="left">Node name</th>
<th valign="middle" align="left">Boolean rule</th>
<th valign="middle" align="left">References</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">IFN-<italic>&#x3b3;</italic>R</td>
<td valign="middle" align="left">IFNGR</td>
<td valign="middle" align="left">IFNGE</td>
<td valign="middle" align="left">10.1038/s41577-018-0029-z</td>
</tr>
<tr>
<td valign="middle" align="left">GM-CSFR<italic>&#x3b1;</italic></td>
<td valign="middle" align="left">CSF2RA</td>
<td valign="middle" align="left">GMCSFE</td>
<td valign="middle" align="left">10.3109/08977194.2011.649919</td>
</tr>
<tr>
<td valign="middle" align="left">IL-1R</td>
<td valign="middle" align="left">IL1R</td>
<td valign="middle" align="left">IL1BE | IL1BOUT</td>
<td valign="middle" align="left">10.1146/annurev.immunol.021908.132612</td>
</tr>
<tr>
<td valign="middle" align="left">TLR4</td>
<td valign="middle" align="left">TLR4</td>
<td valign="middle" align="left">LPSE</td>
<td valign="middle" align="left">10.1016/j.preghy.2020.06.002</td>
</tr>
<tr>
<td valign="middle" align="left">Fc<italic>&#x3b3;</italic>R</td>
<td valign="middle" align="left">FCGR</td>
<td valign="middle" align="left">IGGC | (IGGC &amp; IL1BE) | MINCLE</td>
<td valign="middle" align="left">10.3389/fimmu.2020.01393; 10.3389/fimmu.2017.00280; 10.1111/imm.12167; 10.1016/j.immuni.2013.03.010</td>
</tr>
<tr>
<td valign="middle" align="left">IL-4R<italic>&#x3b1;</italic></td>
<td valign="middle" align="left">IL4RA</td>
<td valign="middle" align="left">IL4E</td>
<td valign="middle" align="left">10.1046/j.1365-2567.1999.00711.x</td>
</tr>
<tr>
<td valign="middle" align="left">IL-10R</td>
<td valign="middle" align="left">IL10R</td>
<td valign="middle" align="left">IL10E | IL10OUT</td>
<td valign="middle" align="left">10.3389/fimmu.2023.1188750</td>
</tr>
<tr>
<td valign="middle" align="left">STAT1</td>
<td valign="middle" align="left">STAT1</td>
<td valign="middle" align="left">IFNGR &amp;!(SOCS1 | STAT3)</td>
<td valign="middle" align="left">10.1038/s41392-021-00791-1; 10.1038/s41392-023-01468-7; 10.2147/CMAR.S182105</td>
</tr>
<tr>
<td valign="middle" align="left">STAT5</td>
<td valign="middle" align="left">STAT5</td>
<td valign="middle" align="left">CSF2RA &amp;!(STAT3 | IRF4 | SOCS1)</td>
<td valign="middle" align="left">10.3389/fphys.2018.01659; 10.1038/s41392-021-00791-1</td>
</tr>
<tr>
<td valign="middle" align="left">NF-<inline-formula>
<mml:math display="inline" id="im24"><mml:mi>&#x3ba;</mml:mi></mml:math></inline-formula>B</td>
<td valign="middle" align="left">NFKB</td>
<td valign="middle" align="left">IL1R | NEMOIKKB | CARD9 | AKT | PKC | (RIP1 &amp; TRAF2 &amp; CIAP) &amp;!(STAT3 | PPARG | KLF4 | CREB1)</td>
<td valign="middle" align="left">10.3389/fphys.2018.01659; 10.1182/blood-2010-07-273417; 10.1146/annurev.immunol.16.1.225; 10.1073/pnas.97.7.3394; 10.1038/nature04926; 10.1038/43466; 10.3892/ijo.2014.2578; 10.1126/science.1071924</td>
</tr>
<tr>
<td valign="middle" align="left">PPAR<italic>&#x3b3;</italic></td>
<td valign="middle" align="left">PPARG</td>
<td valign="middle" align="left">IL4RA</td>
<td valign="middle" align="left">10.1038/nature05894</td>
</tr>
<tr>
<td valign="middle" align="left">STAT6</td>
<td valign="middle" align="left">STAT6</td>
<td valign="middle" align="left">IL4RA &amp;!STAT1</td>
<td valign="middle" align="left">10.3389/fphys.2018.01659; 10.4049/jimmunol.164.5.2303</td>
</tr>
<tr>
<td valign="middle" align="left">JMJD3</td>
<td valign="middle" align="left">JMJD3</td>
<td valign="middle" align="left">IL4RA</td>
<td valign="middle" align="left">10.1038/ni.1920S</td>
</tr>
<tr>
<td valign="middle" align="left">STAT3</td>
<td valign="middle" align="left">STAT3</td>
<td valign="middle" align="left">(IL10R | (ERK &amp; P38)) &amp;! (PPARG | SOCS3)</td>
<td valign="middle" align="left">10.1242/dmm.024745; 10.1146/annurev.immunol.19.1.683; 10.4049/jimmunol.175.1.469</td>
</tr>
<tr>
<td valign="middle" align="left">SOCS3</td>
<td valign="middle" align="left">SOCS3</td>
<td valign="middle" align="left">NFKB | STAT1</td>
<td valign="middle" align="left">10.1038/s41392-023-01452-1</td>
</tr>
<tr>
<td valign="middle" align="left">IRF3</td>
<td valign="middle" align="left">IRF3</td>
<td valign="middle" align="left">TBK1IKKI | NEMOTBK1IKKE</td>
<td valign="middle" align="left">10.1038/ni921; 10.1074/jbc.M205069200</td>
</tr>
<tr>
<td valign="middle" align="left">ERK</td>
<td valign="middle" align="left">ERK</td>
<td valign="middle" align="left">FCGR | MKK1/2 | PI3K</td>
<td valign="middle" align="left">10.1038/nri2206</td>
</tr>
<tr>
<td valign="middle" align="left">KLF4</td>
<td valign="middle" align="left">KLF4</td>
<td valign="middle" align="left">STAT6</td>
<td valign="middle" align="left">10.1172/JCI45444</td>
</tr>
<tr>
<td valign="middle" align="left">SOCS1</td>
<td valign="middle" align="left">SOCS1</td>
<td valign="middle" align="left">STAT6 | IFNABOUT</td>
<td valign="middle" align="left">10.1074/jbc.M403223200</td>
</tr>
<tr>
<td valign="middle" align="left">IRF4</td>
<td valign="middle" align="left">IRF4</td>
<td valign="middle" align="left">JMJD3</td>
<td valign="middle" align="left">10.1038/ni.1920</td>
</tr>
<tr>
<td valign="middle" align="left">Produced IL-1<italic>&#x3b2;</italic></td>
<td valign="middle" align="left">IL1BOUT</td>
<td valign="middle" align="left">NFKB | (NFKB &amp; AP1)</td>
<td valign="middle" align="left">10.1038/sigtrans.2017.23</td>
</tr>
<tr>
<td valign="middle" align="left">Produced IL-12</td>
<td valign="middle" align="left">IL12OUT</td>
<td valign="middle" align="left">STAT1 | (STAT5 &amp; NFKB) | (AP1 &amp; NFKB)</td>
<td valign="middle" align="left">10.1038/nri1001</td>
</tr>
<tr>
<td valign="middle" align="left">TAK1/2/3</td>
<td valign="middle" align="left">TAK123</td>
<td valign="middle" align="left">MYD88</td>
<td valign="middle" align="left">10.14348/molcells.2023.2193</td>
</tr>
<tr>
<td valign="middle" align="left">JNK/MAPK</td>
<td valign="middle" align="left">JNKMAPK</td>
<td valign="middle" align="left">TAK123</td>
<td valign="middle" align="left">10.14348/molcells.2023.2193</td>
</tr>
<tr>
<td valign="middle" align="left">ERK1/2</td>
<td valign="middle" align="left">ERK12</td>
<td valign="middle" align="left">JNKMAPK</td>
<td valign="middle" align="left">10.14348/molcells.2023.2193</td>
</tr>
<tr>
<td valign="middle" align="left">MSK1/2</td>
<td valign="middle" align="left">MSK12</td>
<td valign="middle" align="left">ERK12 | P38</td>
<td valign="middle" align="left">10.14348/molcells.2023.2193</td>
</tr>
<tr>
<td valign="middle" align="left">GSK-3<italic>&#x3b2;</italic></td>
<td valign="middle" align="left">GSK3<italic>&#x3b2;</italic></td>
<td valign="middle" align="left">!AKT3 |!AKT1</td>
<td valign="middle" align="left">10.14348/molcells.2023.2193; 10.1186/s12950-023-00360-z; 10.4049/jimmunol.1601515</td>
</tr>
<tr>
<td valign="middle" align="left">Produced IL-10</td>
<td valign="middle" align="left">IL10OUT</td>
<td valign="middle" align="left">PPARG | STAT6 | JMJD3 | STAT3 | (CREB1 &amp; AP1)</td>
<td valign="middle" align="left">10.1038/nri2711; 10.14348/molcells.2023.2193; 10.1016/j.smim.2019.101324; 10.7554/eLife.85964; 10.1016/j.cmet.2007.06.010; 10.1016/j.intimp.2020.107266</td>
</tr>
<tr>
<td valign="middle" align="left">Akt1</td>
<td valign="middle" align="left">AKT1</td>
<td valign="middle" align="left">PI3k &amp;!IFNGR</td>
<td valign="middle" align="left">10.1186/s12950-023-00360-z</td>
</tr>
<tr>
<td valign="middle" align="left">Akt3</td>
<td valign="middle" align="left">AKT3</td>
<td valign="middle" align="left">PI3k &amp;!IFNGR</td>
<td valign="middle" align="left">10.1186/s12950-023-00360-z</td>
</tr>
<tr>
<td valign="middle" align="left">TLR2</td>
<td valign="middle" align="left">TLR2</td>
<td valign="middle" align="left">LP</td>
<td valign="middle" align="left">10.1189/jlb.0907656; 10.1016/j.immuni.2009.11.008</td>
</tr>
<tr>
<td valign="middle" align="left">TLR3</td>
<td valign="middle" align="left">TLR3</td>
<td valign="middle" align="left">DSRNA</td>
<td valign="middle" align="left">10.1089/jir.2014.0034</td>
</tr>
<tr>
<td valign="middle" align="left">TLR7</td>
<td valign="middle" align="left">TLR7</td>
<td valign="middle" align="left">SSRNA</td>
<td valign="middle" align="left">10.1073/pnas.0400937101</td>
</tr>
<tr>
<td valign="middle" align="left">TLR8</td>
<td valign="middle" align="left">TLR8</td>
<td valign="middle" align="left">SSRNA</td>
<td valign="middle" align="left">10.1016/j.bmc.2017.11.020</td>
</tr>
<tr>
<td valign="middle" align="left">TLR9</td>
<td valign="middle" align="left">TLR9</td>
<td valign="middle" align="left">CPGDNA</td>
<td valign="middle" align="left">10.2174/1566524023362159</td>
</tr>
<tr>
<td valign="middle" align="left">MyD88</td>
<td valign="middle" align="left">MYD88</td>
<td valign="middle" align="left">TLR2 | TLR4 | TLR7 | TLR8 | TLR9</td>
<td valign="middle" align="left">10.1038/ni.1863; 10.1038/35100529</td>
</tr>
<tr>
<td valign="middle" align="left">IRAK4</td>
<td valign="middle" align="left">IRAK4</td>
<td valign="middle" align="left">MYD88</td>
<td valign="middle" align="left">10.1016/j.immuni.2008.09.015</td>
</tr>
<tr>
<td valign="middle" align="left">IRAK1/2</td>
<td valign="middle" align="left">IRAK1/2</td>
<td valign="middle" align="left">IRAK4</td>
<td valign="middle" align="left">10.1074/jbc.M700548200; 10.1084/jem.20061523</td>
</tr>
<tr>
<td valign="middle" align="left">TRAF6</td>
<td valign="middle" align="left">TRAF6</td>
<td valign="middle" align="left">IRAK1/2</td>
<td valign="middle" align="left">10.3389/fimmu.2023.1133354</td>
</tr>
<tr>
<td valign="middle" align="left">TAB2/3/TAK</td>
<td valign="middle" align="left">TAB2/3TAK</td>
<td valign="middle" align="left">TRAF6 | RIP1</td>
<td valign="middle" align="left">10.3389/fimmu.2020.608976; 10.1038/nature08247</td>
</tr>
<tr>
<td valign="middle" align="left">MKK3/6</td>
<td valign="middle" align="left">MKK3/6</td>
<td valign="middle" align="left">TAB2/3TAK</td>
<td valign="middle" align="left">10.1152/ajpheart.00186.2005; 10.15252/embr.201948035</td>
</tr>
<tr>
<td valign="middle" align="left">p38</td>
<td valign="middle" align="left">P38</td>
<td valign="middle" align="left">MKK3/6</td>
<td valign="middle" align="left">10.1016/j.bbamcr.2007.03.010</td>
</tr>
<tr>
<td valign="middle" align="left">CREB1</td>
<td valign="middle" align="left">CREB1</td>
<td valign="middle" align="left">MSK1/2 &amp;!GSK3<italic>&#x3b2;</italic></td>
<td valign="middle" align="left">10.14348/molcells.2023.2193</td>
</tr>
<tr>
<td valign="middle" align="left">MKK4/7</td>
<td valign="middle" align="left">MKK4/7</td>
<td valign="middle" align="left">TAB2/3TAK</td>
<td valign="middle" align="left">10.1016/j.tips.2012.06.007</td>
</tr>
<tr>
<td valign="middle" align="left">JNK</td>
<td valign="middle" align="left">JNK</td>
<td valign="middle" align="left">MKK4/7 | PI3K</td>
<td valign="middle" align="left">10.4049/jimmunol.180.6.4218; 10.1007/s00018-013-1322-4; 10.4049/jimmunol.0801352</td>
</tr>
<tr>
<td valign="middle" align="left">c-Jun</td>
<td valign="middle" align="left">CJUN</td>
<td valign="middle" align="left">JNK</td>
<td valign="middle" align="left">10.1016/s0092-8674(00)00116-1</td>
</tr>
<tr>
<td valign="middle" align="left">MKK1/2</td>
<td valign="middle" align="left">MKK1/2</td>
<td valign="middle" align="left">NEMOIKKB</td>
<td valign="middle" align="left">10.1016/j.jbc.2022.101864</td>
</tr>
<tr>
<td valign="middle" align="left">c-Fos</td>
<td valign="middle" align="left">CFOS</td>
<td valign="middle" align="left">ERK</td>
<td valign="middle" align="left">10.1074/jbc.C500353200</td>
</tr>
<tr>
<td valign="middle" align="left">AP-1</td>
<td valign="middle" align="left">AP1</td>
<td valign="middle" align="left">CJUN | CFOS | MSK12 &amp;!GSK3<italic>&#x3b2;</italic></td>
<td valign="middle" align="left">10.1016/j.bbalip.2014.05.007; 10.1006/excr.2001.5180; 10.1038/nri2711</td>
</tr>
<tr>
<td valign="middle" align="left">NEMO/IKK<italic>&#x3b2;</italic></td>
<td valign="middle" align="left">NEMOIKKB</td>
<td valign="middle" align="left">TAB2/3TAK</td>
<td valign="middle" align="left">10.1016/j.molcel.2004.08.008</td>
</tr>
<tr>
<td valign="middle" align="left">RIP1</td>
<td valign="middle" align="left">RIP1</td>
<td valign="middle" align="left">TRIF | TRADD</td>
<td valign="middle" align="left">10.1074/jbc.M506831200; 10.1016/j.bbrc.2013.12.068</td>
</tr>
<tr>
<td valign="middle" align="left">Endosomal TLR4</td>
<td valign="middle" align="left">TLR4END</td>
<td valign="middle" align="left">TLR4</td>
<td valign="middle" align="left">10.2337/db21-0426</td>
</tr>
<tr>
<td valign="middle" align="left">TRIF</td>
<td valign="middle" align="left">TRIF</td>
<td valign="middle" align="left">TLR3 | TLR4END</td>
<td valign="middle" align="left">10.1631/jzus.B2000808; 10.1074/jbc.M506831200</td>
</tr>
<tr>
<td valign="middle" align="left">TRAF3</td>
<td valign="middle" align="left">TRAF3</td>
<td valign="middle" align="left">TRIF | (TRADD &amp; MAVS) | (IRAK1/2 &amp; TLR7) | (IRAK1/2 &amp; TLR8) | (IRAK1/2 &amp; TLR9)</td>
<td valign="middle" align="left">10.3389/fimmu.2019.00104; 10.1111/j.1600-065X.2011.01055.x; 10.1038/cr.2011.2; 10.3389/fimmu.2014.00461</td>
</tr>
<tr>
<td valign="middle" align="left">TBK1/IKK<inline-formula>
<mml:math display="inline" id="im25"><mml:mi>&#x2208;</mml:mi></mml:math></inline-formula></td>
<td valign="middle" align="left">TBK1IKKI</td>
<td valign="middle" align="left">TRAF3 &amp; TRIF</td>
<td valign="middle" align="left">10.1038/nri2998; 10.1074/jbc.M311629200</td>
</tr>
<tr>
<td valign="middle" align="left">IKK<italic>&#x3b1;</italic></td>
<td valign="middle" align="left">IKKA</td>
<td valign="middle" align="left">TRAF3 &amp; IRAK1/2</td>
<td valign="middle" align="left">10.1074/jbc.M109.076091; 10.3389/fimmu.2014.00553</td>
</tr>
<tr>
<td valign="middle" align="left">IRF7</td>
<td valign="middle" align="left">IRF7</td>
<td valign="middle" align="left">IKKA | NEMOTBK1IKKE</td>
<td valign="middle" align="left">10.1016/j.molimm.2007.10.034; 10.1038/ni1465</td>
</tr>
<tr>
<td valign="middle" align="left">Produced IL-6</td>
<td valign="middle" align="left">IL6OUT</td>
<td valign="middle" align="left">NFKB | (AP1)</td>
<td valign="middle" align="left">10.1093/cvr/cvq076; 10.1097/00024382-200014030-00025; 10.3389/fimmu.2016.00604</td>
</tr>
<tr>
<td valign="middle" align="left">Produced IL-18</td>
<td valign="middle" align="left">IL18OUT</td>
<td valign="middle" align="left">NFKB &amp; AP1</td>
<td valign="middle" align="left">10.4049/jimmunol.1001829; 10.1016/j.cyto.2014.05.003; 10.1016/S0006-291X(02)02433-6</td>
</tr>
<tr>
<td valign="middle" align="left">Produced IL-33</td>
<td valign="middle" align="left">IL33OUT</td>
<td valign="middle" align="left">NFKB &amp; AP1</td>
<td valign="middle" align="left">10.1038/ni.3772; 10.1002/eji.201040718</td>
</tr>
<tr>
<td valign="middle" align="left">Produced IFN-<italic>&#x3b1;</italic></td>
<td valign="middle" align="left">IFNABOUT</td>
<td valign="middle" align="left">IRF3 | IRF7</td>
<td valign="middle" align="left">10.1016/s1074-7613(00)00053-4; 10.1016/j.molimm.2007.10.034</td>
</tr>
<tr>
<td valign="middle" align="left">Phagocytosis</td>
<td valign="middle" align="left">PHAGOCYTOSIS</td>
<td valign="middle" align="left">(WAVE &amp; WASP) | RAC</td>
<td valign="middle" align="left">10.1155/2023/3577334; 10.1016/j.celrep.2016.09.039; 10.4161/cib.3.2.10759; 10.4161/sgtp.27952</td>
</tr>
<tr>
<td valign="middle" align="left">Phagosome</td>
<td valign="middle" align="left">PHAGOSOME</td>
<td valign="middle" align="left">PHAGOCYTOSIS</td>
<td valign="middle" align="left">10.1097/MOT.0000000000000313</td>
</tr>
<tr>
<td valign="middle" align="left">Processing</td>
<td valign="middle" align="left">PROCESSING</td>
<td valign="middle" align="left">PHAGOCYTOSOME | ENDOSOME</td>
<td valign="middle" align="left">10.1016/j.coi.2007.10.010; 10.1146/annurev-immunol-032712-095910</td>
</tr>
<tr>
<td valign="middle" align="left">MHC-II</td>
<td valign="middle" align="left">MHC2</td>
<td valign="middle" align="left">PROCESSING</td>
<td valign="middle" align="left">10.1146/annurev-immunol-032712-095910</td>
</tr>
<tr>
<td valign="middle" align="left">ITAM</td>
<td valign="middle" align="left">ITAM</td>
<td valign="middle" align="left">FCGR</td>
<td valign="middle" align="left">10.1146/annurev.immunol.15.1.203</td>
</tr>
<tr>
<td valign="middle" align="left">Syk</td>
<td valign="middle" align="left">SYK</td>
<td valign="middle" align="left">ITAM | SRC | CA | DAP12 | (HCK &amp; FGR)</td>
<td valign="middle" align="left">10.1073/pnas.94.5.1919; 10.1074/jbc.M804942200; 10.1016/j.molcel.2008.06.023; 10.1182/bloodadvances.2021006147</td>
</tr>
<tr>
<td valign="middle" align="left">CARD9</td>
<td valign="middle" align="left">CARD9</td>
<td valign="middle" align="left">SYK</td>
<td valign="middle" align="left">10.1016/j.immuni.2018.08.024</td>
</tr>
<tr>
<td valign="middle" align="left">Vav</td>
<td valign="middle" align="left">VAV</td>
<td valign="middle" align="left">SYK</td>
<td valign="middle" align="left">10.1016/s1074-7613(00)80273-3</td>
</tr>
<tr>
<td valign="middle" align="left">Rac</td>
<td valign="middle" align="left">RAC</td>
<td valign="middle" align="left">VAV</td>
<td valign="middle" align="left">10.1128/MCB.25.10.4211-4220.2005; 10.3389/fimmu.2019.02585</td>
</tr>
<tr>
<td valign="middle" align="left">Cdc42</td>
<td valign="middle" align="left">CDC42</td>
<td valign="middle" align="left">VAV</td>
<td valign="middle" align="left">10.1161/ATVBAHA.118.312087</td>
</tr>
<tr>
<td valign="middle" align="left">WASP</td>
<td valign="middle" align="left">WASP</td>
<td valign="middle" align="left">RAC</td>
<td valign="middle" align="left">10.1016/j.cub.2019.10.036</td>
</tr>
<tr>
<td valign="middle" align="left">WAVE</td>
<td valign="middle" align="left">WAVE</td>
<td valign="middle" align="left">CDC42</td>
<td valign="middle" align="left">10.3389/fmicb.2018.00360</td>
</tr>
<tr>
<td valign="middle" align="left">Ca2+</td>
<td valign="middle" align="left">CA</td>
<td valign="middle" align="left">PLC</td>
<td valign="middle" align="left">10.1038/sigtrans.2017.23; 10.1016/j.bbamcr.2021.119040</td>
</tr>
<tr>
<td valign="middle" align="left">Lyn</td>
<td valign="middle" align="left">LYN</td>
<td valign="middle" align="left">FCAR</td>
<td valign="middle" align="left">10.1016/j.exppara.2020.107970; 10.1111/j.1600-065X.2008.00758.x</td>
</tr>
<tr>
<td valign="middle" align="left">Fyn</td>
<td valign="middle" align="left">FYN</td>
<td valign="middle" align="left">FCAR</td>
<td valign="middle" align="left">10.1111/j.1600-065X.2008.00758.x</td>
</tr>
<tr>
<td valign="middle" align="left">DAP12</td>
<td valign="middle" align="left">DAP12</td>
<td valign="middle" align="left">FYN | LYN</td>
<td valign="middle" align="left">10.1016/j.cellsig.2012.02.014; 10.1002/alz.088509</td>
</tr>
<tr>
<td valign="middle" align="left">PI3K</td>
<td valign="middle" align="left">PI3K</td>
<td valign="middle" align="left">SYK | MYD88</td>
<td valign="middle" align="left">10.1074/jbc.M111.255125; 10.14348/molcells.2023.2193</td>
</tr>
<tr>
<td valign="middle" align="left">PLC</td>
<td valign="middle" align="left">PLC</td>
<td valign="middle" align="left">SYK</td>
<td valign="middle" align="left">10.1016/s1074-7613(00)80012-6</td>
</tr>
<tr>
<td valign="middle" align="left">Akt</td>
<td valign="middle" align="left">AKT</td>
<td valign="middle" align="left">PI3K</td>
<td valign="middle" align="left">10.3892/mmr.2018.9713</td>
</tr>
<tr>
<td valign="middle" align="left">PKC</td>
<td valign="middle" align="left">PKC</td>
<td valign="middle" align="left">PLC</td>
<td valign="middle" align="left">10.1182/blood.V72.2.739.739</td>
</tr>
<tr>
<td valign="middle" align="left">CD11b/CD18</td>
<td valign="middle" align="left">CD11BCD18</td>
<td valign="middle" align="left">IC3B</td>
<td valign="middle" align="left">10.1073/pnas.91.22.10680</td>
</tr>
<tr>
<td valign="middle" align="left">Hck</td>
<td valign="middle" align="left">HCK</td>
<td valign="middle" align="left">CD11BCD18</td>
<td valign="middle" align="left">10.1016/j.jare.2023.02.010; 10.1016/j.febslet.2006.06.099</td>
</tr>
<tr>
<td valign="middle" align="left">Fgr</td>
<td valign="middle" align="left">FGR</td>
<td valign="middle" align="left">CD11BCD18</td>
<td valign="middle" align="left">10.1038/s41420-023-01538-3</td>
</tr>
<tr>
<td valign="middle" align="left">Fc<italic>&#x3b1;</italic>R</td>
<td valign="middle" align="left">FCAR</td>
<td valign="middle" align="left">IGGA</td>
<td valign="middle" align="left">10.1517/14728222.2014.877891</td>
</tr>
<tr>
<td valign="middle" align="left">mTOR</td>
<td valign="middle" align="left">MTOR</td>
<td valign="middle" align="left">AKT | NFKB</td>
<td valign="middle" align="left">10.1007/s12282-024-01567-5; 10.1038/sigtrans.2017.23</td>
</tr>
<tr>
<td valign="middle" align="left">mTORC1</td>
<td valign="middle" align="left">MTORC1</td>
<td valign="middle" align="left">(MTOR &amp; (AKT | NFKB) &amp;!AMPK)</td>
<td valign="middle" align="left">10.1242/jcs.051011</td>
</tr>
<tr>
<td valign="middle" align="left">mTORC2</td>
<td valign="middle" align="left">MTORC2</td>
<td valign="middle" align="left">(MTOR &amp; AMPK) | (MTOR &amp; IL4E)</td>
<td valign="middle" align="left">10.1126/scisignal.aav3249; 10.1126/scisignal.267pe27; 10.1016/j.immuni.2016.09.016</td>
</tr>
<tr>
<td valign="middle" align="left">LKB1</td>
<td valign="middle" align="left">LKB1</td>
<td valign="middle" align="left">(AKT &amp; AMPATPratio) | IL4E | IL10E</td>
<td valign="middle" align="left">10.3389/fmicb.2019.00520; 10.4049/jimmunol.181.12.8633</td>
</tr>
<tr>
<td valign="middle" align="left">AMPK</td>
<td valign="middle" align="left">AMPK</td>
<td valign="middle" align="left">((LKB1 | (CA | AKT) &amp; AMPATPratio) &amp;!MTORC1)</td>
<td valign="middle" align="left">10.3389/fmicb.2019.00520; 10.4049/jimmunol.181.12.8633</td>
</tr>
<tr>
<td valign="middle" align="left">Glycolysis</td>
<td valign="middle" align="left">Glycolysis</td>
<td valign="middle" align="left">((MTORC1 | HIF1A) &amp; GLC) &amp;!AMPATPratio</td>
<td valign="middle" align="left">10.3892/ijo.2020.5152; 10.1113/JP280572</td>
</tr>
<tr>
<td valign="middle" align="left">OXPHOS</td>
<td valign="middle" align="left">OXPHOS</td>
<td valign="middle" align="left">AMPK &amp; FA</td>
<td valign="middle" align="left">10.1038/nrm.2017.95; 10.1074/jbc.M110.139493</td>
</tr>
<tr>
<td valign="middle" align="left">AMP/ATP ratio</td>
<td valign="middle" align="left">AMPATPratio</td>
<td valign="middle" align="left">Glycolysis &amp;!OXPHOS</td>
<td valign="middle" align="left">10.3945/ajcn.110.001925</td>
</tr>
<tr>
<td valign="middle" align="left">HIF-1<italic>&#x3b1;</italic></td>
<td valign="middle" align="left">HIF1A</td>
<td valign="middle" align="left">!O2 &amp; AKT</td>
<td valign="middle" align="left">10.1016/j.micinf.2016.11.003; 10.1038/s41523-023-00598-z</td>
</tr>
<tr>
<td valign="middle" align="left">RIG-I</td>
<td valign="middle" align="left">RIG1</td>
<td valign="middle" align="left">CITDSRNA | CITSSRNA</td>
<td valign="middle" align="left">10.1084/jem.20081210; 10.1016/j.molcel.2022.11.018</td>
</tr>
<tr>
<td valign="middle" align="left">MAVS</td>
<td valign="middle" align="left">MAVS</td>
<td valign="middle" align="left">RIG1</td>
<td valign="middle" align="left">10.1016/j.coviro.2015.04.004</td>
</tr>
<tr>
<td valign="middle" align="left">TRADD</td>
<td valign="middle" align="left">TRADD</td>
<td valign="middle" align="left">MAVS | TNFR1</td>
<td valign="middle" align="left">10.1371/journal.ppat.1004020; 10.1016/0092-8674(95)90070-5</td>
</tr>
<tr>
<td valign="middle" align="left">NEMO/IKK<italic>&#x3b1;</italic>/<italic>&#x3b2;</italic></td>
<td valign="middle" align="left">NEMOIKKAB</td>
<td valign="middle" align="left">RIP1 &amp; TRADD</td>
<td valign="middle" align="left">10.1016/j.molcel.2006.03.026</td>
</tr>
<tr>
<td valign="middle" align="left">NEMO/TBK1/IKK<inline-formula>
<mml:math display="inline" id="im26"><mml:mi>&#x2208;</mml:mi></mml:math></inline-formula></td>
<td valign="middle" align="left">NEMOTBK1IKKE</td>
<td valign="middle" align="left">TRAF3 &amp; TRADD</td>
<td valign="middle" align="left">10.1016/j.immuni.2008.03.013</td>
</tr>
<tr>
<td valign="middle" align="left">TNFR1</td>
<td valign="middle" align="left">TNFR1</td>
<td valign="middle" align="left">TNFA | TNFAOUT</td>
<td valign="middle" align="left">10.1615/critreveukargeneexpr.v20.i2.10</td>
</tr>
<tr>
<td valign="middle" align="left">TRAF2</td>
<td valign="middle" align="left">TRAF2</td>
<td valign="middle" align="left">TRADD</td>
<td valign="middle" align="left">10.1016/s0092-8674(00)80984-8</td>
</tr>
<tr>
<td valign="middle" align="left">Produced TNF<italic>&#x3b1;</italic></td>
<td valign="middle" align="left">TNFAOUT</td>
<td valign="middle" align="left">NFKB</td>
<td valign="middle" align="left">10.1016/j.smim.2014.05.004</td>
</tr>
<tr>
<td valign="middle" align="left">Dectin-1</td>
<td valign="middle" align="left">DECTIN1</td>
<td valign="middle" align="left">NFKB</td>
<td valign="middle" align="left">10.18632/aging.20492; 10.1038/ni.1692</td>
</tr>
<tr>
<td valign="middle" align="left">Dectin-2</td>
<td valign="middle" align="left">DECTIN2</td>
<td valign="middle" align="left">NFKB</td>
<td valign="middle" align="left">10.1101/cshperspect.a002352</td>
</tr>
<tr>
<td valign="middle" align="left">Mannose receptor</td>
<td valign="middle" align="left">MR</td>
<td valign="middle" align="left">NFKB</td>
<td valign="middle" align="left">10.3389/fimmu.2021.765034</td>
</tr>
<tr>
<td valign="middle" align="left">CLEC10A</td>
<td valign="middle" align="left">CLEC10A</td>
<td valign="middle" align="left">NFKB</td>
<td valign="middle" align="left">10.1038/nri.2016.55</td>
</tr>
<tr>
<td valign="middle" align="left">Mincle</td>
<td valign="middle" align="left">MINCLE</td>
<td valign="middle" align="left">NFKB</td>
<td valign="middle" align="left">10.3389/fimmu.2017.00861; 10.1158/2326-6066.CIR-19-0782</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>*Logical connectives symbols: and &#x2192; &amp;, or &#x2192; |, not &#x2192;!.</p>
<p>** Citations for DOI&#x2019;s are provided in <xref ref-type="supplementary-material" rid="SM1"><bold>Supplementary Table 1</bold></xref>.</p></fn>
</table-wrap-foot>
</table-wrap>
<p>Inflammatory pathways are represented in <xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3A</bold></xref>, which displays the convergence of activating and inhibitory signals on the NF<italic>&#x3ba;</italic>b node, as well as the consequent production of inflammatory cytokines (TNF<italic>&#x3b1;</italic>, IL-1<italic>&#x3b2;</italic>, IL-12, IL-6, IL-18, and IL-33). This module includes the activity of metabolic elements such as mTOR and mTORC1, as well as transcription factors and cofactors such as CREB1, AP-1, IRF3 and IRF7 that are either activated by the TNF<italic>&#x3b1;</italic> and FC<italic>&#x3b3;</italic> receptors, or by TLR engagement. Since the effects of Akt on macrophage polarization appear to be Akt isoform-specific (<xref ref-type="bibr" rid="B30">30</xref>), its isoforms Akt1, Akt2 and Akt3, have been incorporated in the network regulatory pathways (<xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3B</bold></xref>). In particular, experiments with macrophages deficient in Akt1 or Akt2 revealed that this default gives rise to M1 and M2 macrophages, respectively (<xref ref-type="bibr" rid="B31">31</xref>).</p>
<p>The pathways leading to the anti-inflammatory role of CREB1 are shown in <xref ref-type="fig" rid="f7"><bold>Figure&#xa0;3B</bold></xref>, highlighting GSK3<italic>&#x3b2;</italic> as inhibitor of the CREB1 function. It can be observed that this module displays the downstream pathway:</p>
<disp-formula>
<mml:math display="block" id="IM5"><mml:mrow><mml:mtext>IFNGE&#xa0;</mml:mtext><mml:mo>&#x2192;</mml:mo><mml:mtext>&#xa0;IFNGR&#xa0;</mml:mtext><mml:mo>&#x219b;</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mtext>AKT</mml:mtext><mml:mn>1</mml:mn><mml:mtext>&#xa0;or&#xa0;AKT</mml:mtext><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>&#x219b;</mml:mo><mml:mn>&#xa0;GS3KB&#xa0;</mml:mn><mml:mo>&#x219b;</mml:mo><mml:mn>CREB1&#xa0;</mml:mn><mml:mo>&#x219b;</mml:mo><mml:mtext>NFKB</mml:mtext></mml:mrow></mml:math>
</disp-formula>
<p>which involves four consecutive inhibitory interactions, leading to the activation of the last downstream element; therefore, the presence of IFN-<italic>&#x3b3;</italic> in the cell microenvironment promotes the activation of NF-<italic>&#x3ba;</italic>B. Conversely, in the absence of IFN-<italic>&#x3b3;</italic>, an anti-inflammatory macrophage profile may arise, as may be inferred from the middle factors in the route: upon activation (by PI3K) the Akt1 and Akt3 mediators hinder the action of the constitutively expressed factor GSK3<italic>&#x3b2;</italic> (<xref ref-type="bibr" rid="B32">32</xref>), leading to anti-inflammatory effects of CREB1 through NF-<italic>&#x3ba;</italic>B inhibition.</p>
<p><xref ref-type="fig" rid="f3"><bold>Figure&#xa0;3C</bold></xref> shows a module for AMPK-controlled glycolysis and oxidative phosphorylation (OXPHOS), reflecting the metabolic profiles of M1 and M2 phenotypes. In this module, AMPK is a central energy sensor of the AMP/ATP ratio and involves a negative feedback loop with mTORC1, defining a switch driving either OXPHOS or glycolytic activity.</p>
<p>The signaling pathways induced by the exogenous immunoregulatory cytokines IL-4 and IL-10 are shown in <xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4</bold></xref>. Receptor signaling by these cytokines leads to inhibition of NF<italic>&#x3ba;</italic>b, promotes the production of IL-10 and the activation of AMPK, directing the macrophage metabolism toward OXPHOS.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<label>3</label>
<title>Results</title>
<sec id="s3_1">
<label>3.1</label>
<title><italic>In silico</italic> reproduction of canonical macrophage phenotypes</title>
<p>We applied the mathematical model to the analysis of a set of relevant initial conditions introduced as inputs of the system (see <xref ref-type="table" rid="T1"><bold>Table&#xa0;1</bold></xref>). <xref ref-type="fig" rid="f5"><bold>Figures&#xa0;5</bold></xref>-<xref ref-type="fig" rid="f8"><bold>8</bold></xref> depict the time evolution of network components induced by diverse cell microenvironments, and <xref ref-type="fig" rid="f9"><bold>Figure&#xa0;9</bold></xref> summarizes the stable states obtained.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Dynamical evolution of monocyte differentiation into the M1, M2a, M2b, and M2c phenotypes induced by microenvironment stimuli. <bold>(A)</bold> LPS+IFN<italic>&#x3b3;</italic> combination induces full M1 differentiation with a glycolytic metabolism and induction of pro-inflammatory cytokines. <bold>(B)</bold> IL-4 stimulation alone drives M2a expression markers with OXPHOS activity and IL-10 expression. <bold>(C)</bold> LPS+IL-1<italic>&#x3b2;</italic> combination induces a mixed M2b/M2c phenotype, with a glycolytic metabolism, transient production of pro-inflammatory cytokines and steady expression of IL10. <bold>(D)</bold> IL-10 stimulation induces an earlier expression of M2c markers, with an oxidative metabolism and further IL-10 production.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1639005-g005.tif">
<alt-text content-type="machine-generated">Graphs show macrophage activity across various stimuli: M1, M2a, M2b, and M2c inputs. Columns represent metabolism, transcription factors, and markers. Activity levels over time depict responses to different cytokines and markers, highlighting differential expression among macrophage subtypes.</alt-text>
</graphic></fig>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Predicted effects of IL-4 and IL-10 on M1 differentiation. <bold>(A)</bold> LPS induces a mixed M1/M2b/M2c phenotype, with production of pro- and anti-inflammatory cytokines. <bold>(B)</bold> LPS + IFN-g drives a strong M1 polarization, with a glycolytic metabolism and production of all pro-inflammatory cytokines. The M2a and M2c phenotypes are inhibited, while M2b is partially suppressed. <bold>(C)</bold> IL-4 abrogates the activity of NF-&#x3b3;B, with a shift to a mixed M2a/M2b phenotype, with a OXPHOS metabolism and induction of both pro- and anti-inflammatory cytokines. <bold>(D)</bold> IL-10 abrogates the activity of NF-&#x3b3;B and IRF4, with a shift to a mixed M2b/M2c phenotype, with an OXPHOS metabolism and induction of both pro- and anti-inflammatory cytokines.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1639005-g006.tif">
<alt-text content-type="machine-generated">Graphs depicting activity levels of various parameters across different time points and conditions. Panels A to D show changes in microenvironment, metabolism, transcription factors, M1, M2a, M2b, and M2c markers. Each graph line represents specific factors such as Glycolysis, OXPHOS, NF-kB, IFN-γ, IL-10, among others, with distinct variations in each panel.</alt-text>
</graphic></fig>
<fig id="f7" position="float">
<label>Figure&#xa0;7</label>
<caption>
<p>Effect of variable levels of IFN-<italic>&#x3b3;</italic> on CREB1 and NF<italic>&#x3ba;</italic>B in the pro- and anti-inflammatory macrophage differentation. <bold>(A)</bold> The combination of exogenous LPS and IFN-<italic>&#x3b3;</italic> at optimal levels (LPS = 1, IFN-<italic>&#x3b3;</italic> = 1) leads to a prevailing M1 polarization with induction of pro-inflammatory citokines. IFN-<italic>&#x3b3;</italic> impedes de inactivation of the CREB1 inhibitor, GSK3<italic>&#x3b2;</italic>, allowing a stable NF-<italic>&#x3ba;</italic>B activity. <bold>(B)</bold> LPS + 0.75 IFN-<italic>&#x3b3;</italic> still yields an identical expression pattern as in the previous case. <bold>(C)</bold> LPS + 0.50 IFN-<italic>&#x3b3;</italic>, also leads to a pro-inflammatory pattern, but now AKT1 and AKT3 are expressed at a middle level. <bold>(D)</bold> LPS + 0.25 IFN-<italic>&#x3b3;</italic>, induces the expression of AKT1 and AKT3 at optimal levels, so that GSK3<italic>&#x3b2;</italic> is depleted, allowing the expression of CREB1 and the concomitant inhibition of NF-<italic>&#x3ba;</italic>B. So, the M1 polarization is disrupted, and a mixed M2b/M2c phenotype is generated. <bold>(E)</bold> LPS alone yields identical results as <bold>(D)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1639005-g007.tif">
<alt-text content-type="machine-generated">Grouped bar graphs and line charts depict various module activities under different microenvironments labeled A through E. Each row shows bar graphs for microenvironments and line charts for CREB module, transcription factors, M1 markers, M2a markers, M2b markers, and M2c markers. The y-axis represents activity levels, and the x-axis represents time. Specific markers such as IFN-α, IL-1β, and PPAR-γ are shown with various line types across conditions.</alt-text>
</graphic></fig>
<fig id="f8" position="float">
<label>Figure&#xa0;8</label>
<caption>
<p>Induction of phagocytosis and antigen presentation by IgG immune complexes (IC). Addition of IC induces phagocytosis and antigen processing and presentation to the <bold>(A)</bold> M1 stimulus, <bold>(B)</bold> M1 stimulus+IL-4. <bold>(C)</bold> M1 stimulus composed by ss-RNA+IFN-&#x3b3;, and <bold>(D)</bold> ss-RNA+IFN-&#x3b3; stimulus in the presence of IL-4.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1639005-g008.tif">
<alt-text content-type="machine-generated">Graphs depicting macrophage activity across various conditions. Four panels (A, B, C, D) show changes in metabolism, transcription factors, M1 markers, M2a and M2b markers, and macrophage activity like phagocytosis and endocytosis. Each panel varies in test conditions, depicted over time, showing differences in activity levels for specific markers and processes.</alt-text>
</graphic></fig>
<fig id="f9" position="float">
<label>Figure&#xa0;9</label>
<caption>
<p>Summary of steady-state values of nodes (asymptotic states at a time T = 30) in the microenvironments analyzed in <xref ref-type="fig" rid="f5"><bold>Figures 5</bold></xref>&#x2013;<xref ref-type="fig" rid="f8"><bold>8</bold></xref>. Columns show different treatment conditions. <bold>(A)</bold> M1, M2a, M2b, and M2c profiles induced by stimulation with LPS+INFgamma, IL-4, LPS+IL-1beta, and IL10, respectively. <bold>(B)</bold> Anti-inflammatory effect of IL-4 and IL-10 on the M1profile. <bold>(C)</bold> Effect of variable levels of INFgamma on the M1 profile. <bold>(D)</bold> M1 profiles obtained by stimulation with LPS+INFgamma and ssRNA+INFgamma. Effect  of IL-4 and induction of phagocytosis and antigen presentation by IgG immune complexes (IC).</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1639005-g009.tif">
<alt-text content-type="machine-generated">Four heatmaps labeled A, B, C, and D show binary values of immune responses (1 = green, 0 = red) representing stable states reached across various conditions. Rows represent different immune markers and processes such as NF-kB, IL-10, and phagocytosis, while columns show different treatment conditions like LPS + IFN-g. Each heatmap has distinct patterns indicating variations in immune responses.</alt-text>
</graphic></fig>
<p>The network faithfully reproduces the spectrum of macrophage functional states, known as M1, M2a, M2b, and M2c. <xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5</bold></xref> displays the dynamics of metabolic changes, transcription factor activity, cytokine production and markers associated with the M1, M2a, M2b and M2c phenotypes. It can be observed that co-stimulation with LPS and IFN-<italic>&#x3b3;</italic> drives a full M1 polarization (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5A</bold></xref>). The system converges to a sustained activation of NF-<italic>&#x3ba;</italic>B, a marked increase in glycolytic flux, and robust production of all pro-inflammatory cytokines (IFN-<italic>&#x3b1;</italic>, IL-1<italic>&#x3b2;</italic>, IL-6, IL-12 and TNF-<italic>&#x3b1;</italic>). This outcome reproduces the metabolic and secretory profile typical of classically activated macrophages (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B33">33</xref>). On the other hand, IL-4 alone (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5B</bold></xref>) promotes a M2a state: AMPK-driven oxidative phosphorylation prevalence over glycolysis, activity of PPAR-<italic>&#x3b3;</italic>, JMJD3, and STAT6, and production of IL-10. These features mirror the anti-inflammatory and tissue-repair phenotype described for IL-4&#x2013;stimulated macrophages (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>). When LPS is paired with IL-1<italic>&#x3b2;</italic> (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5C</bold></xref>), the model yields the M2b response: a transient burst of TNF&#x3b1; is induced (similarly to the case of LPS alone (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6A</bold></xref>) Gycolysis remains dominant, and a mixed set of pro- and anti-inflammatory cytokines is produced, with activation of Erk and STAT3 and production of IL-10. This phenotype recapitulates observations that LPS+ IL-1<italic>&#x3b2;</italic> stimuli can generate hybrid profiles (<xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). Finally, IL-10 alone (<xref ref-type="fig" rid="f5"><bold>Figure&#xa0;5D</bold></xref>) drives a full M2c program: sustained OXPHOS metabolism, strong GSK3<italic>&#x3b2;</italic> activation (not shown), and production of IL-10 through the activity of STAT3; pro-inflammatory cytokines are fully suppressed. This result aligns with the immunoregulatory profile induced by IL-10 <italic>in vitro</italic> and <italic>in vivo</italic>, and are consistent with tissue repair functions (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B37">37</xref>). Thus, the monocyte model reproduces the hallmark metabolic and cytokine signatures of canonical macrophage phenotypes.</p>
</sec>
<sec id="s3_2">
<label>3.2</label>
<title>Immunomodulation by IL-4 and IL-10</title>
<p>Signaling events related to immunomodulation by IL-4 and IL-10 were incorporated in the network, as seen in <xref ref-type="fig" rid="f4"><bold>Figure&#xa0;4</bold></xref> and <xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref>. IL-4 receptor signals for stimulation of the histone demethylase JMJD3, STAT6, and PPAR-&#x3b3;, a known inhibitor of NF-&#x3ba;B. STAT6 activation leads to the expression of the IL-10 gene (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B38">38</xref>&#x2013;<xref ref-type="bibr" rid="B40">40</xref>). Likewise, STAT6 activates the Kr&#xfc;ppel-like factor 4 (KLF4), which contributes to the inhibition of NF-<italic>&#x3ba;</italic>B and therefore of the TNF-<italic>&#x3b1;</italic> synthesis. Thus, IL-4 can inhibit NF-<italic>&#x3ba;</italic>B via PPAR-<italic>&#x3b3;</italic> and KLF4 even in the presence of IFN-<italic>&#x3b3;</italic>.</p>
<p>The addition of IL-4 to the LPS+IFN-<italic>&#x3b3;</italic> stimulus promotes partial differentiation to the anti-inflammatory phenotypes M2a and M2b, due to the positive action of JMJD3 on the IRF-4 transcription factor and inhibition of STAT5 (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6C</bold></xref>). On the other hand, activation of STAT6 by IL-4 activates SOCS-1, an inhibitor of STAT1. In the model, inhibition of STAT5 and STAT1 reduces IL-12 production (<xref ref-type="fig" rid="f6"><bold>Figures&#xa0;6C</bold></xref>), as reported (<xref ref-type="bibr" rid="B41">41</xref>, <xref ref-type="bibr" rid="B42">42</xref>). M2 macrophages tend to depend more on mitochondrial oxidative phosphorylation and fatty acid oxidation than glycolysis (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B35">35</xref>, <xref ref-type="bibr" rid="B36">36</xref>, <xref ref-type="bibr" rid="B43">43</xref>, <xref ref-type="bibr" rid="B44">44</xref>). The preferential use of OXPHOS over glycolysis by IL-4 or IL-10-stimulated M2 macrophages is reproduced by the model (<xref ref-type="fig" rid="f6"><bold>Figures&#xa0;6C, D</bold></xref>). Thus, the model reproduced de role of IL-4 and IL-10 in steering differentiation away from a strictly pro-inflammatory state.</p>
</sec>
<sec id="s3_3">
<label>3.3</label>
<title>IFN-<italic>&#x3b3;</italic> drives TLR4-induced inflammation by promoting the activity of the CREB1-inhibitor GSK3<italic>&#x3b2;</italic></title>
<p>The CREB1 inhibitor GSK3<italic>&#x3b2;</italic> is constitutively expressed in monocytes (<xref ref-type="bibr" rid="B19">19</xref>). Upon TLR4 stimulation, GSK3<italic>&#x3b2;</italic> is inhibited via the PI3k-Akt-dependent pathway, specifically through the Akt1 and Akt3 kinases, so that CREB1 remains active, inhibiting the activity of NF-<italic>&#x3ba;</italic>B and promoting the production of IL-10 (<xref ref-type="fig" rid="f3"><bold>Figure 3B</bold></xref>) (reviewed by (<xref ref-type="bibr" rid="B45">45</xref>). The constitutive expression of GSK3<italic>&#x3b2;</italic> was incorporated in the model by asignyinig it an initial 1 value. Simulations showed that TLR4 activation by LPS alone drives the activity of Akt1 and Akt3, inhibition of GSK3<italic>&#x3b2;</italic> and induction of CREB1 activity (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7</bold></xref>). As a result, an incomplete pro-inflammatory profile is obtained, marked by a transient activation of NF-<italic>&#x3ba;</italic>B, with a decay coincident with the induction of CREB1 activity. Accordingly, IL-1<italic>&#x3b2;</italic> and TNF-<italic>&#x3b1;</italic> are transiently produced. The production of IFN-<italic>&#x3b1;</italic> and IL-6, together with the activity of the transcription factors AP-1 and IRF7 and a glycolytic metabolism are observed.</p>
<p>The effect of variable levels of INF-<italic>&#x3b3;</italic> on the M2b/M2c phenotype induced by LPS is shown in <xref ref-type="fig" rid="f7"><bold>Figures&#xa0;7A-D</bold></xref>. INF-<italic>&#x3b3;</italic> inhibits the protein kinases Akt1 and Akt3 activities, allowing the function of GSK3<italic>&#x3b2;</italic>, leading to CREB1 inhibition. In this condition, NF-<italic>&#x3ba;</italic>B is stably active and a complete M1 cytokine profile is induced, as shown in (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7A</bold></xref>). Thus, modeling results are compatible with a relevant role of CREB1 in the inhibition of the pro-inflammatory response via inhibition of NF-<italic>&#x3ba;</italic>B and promotion of IL-10 synthesis. The model predicts that a full activity of NF-<italic>&#x3ba;</italic>B is maintained even when the levels of INF-gamma decreases to half of the optimum value (<xref ref-type="fig" rid="f7"><bold>Figures&#xa0;7B-C</bold></xref>). However, lower amounts of this cytokine (0.25) allow the activity of AKT1 and AKT3, with the concomitant depletion of GSK3<italic>&#x3b2;</italic>, which in turn allows the activity of CREB1 and the subsequent inhibition of NF-<italic>&#x3ba;</italic>B. As a result, the M1 polarization is disrupted, and mixed M2 phenotypes are generated. The absence of IFN-<italic>&#x3b3;</italic> yields the same result (<xref ref-type="fig" rid="f7"><bold>Figures 7D, E</bold></xref>). Thus, the model shows that the stabilization of NF-<italic>&#x3ba;</italic>B activity by IFN-<italic>&#x3b3;</italic> can be reached through inhibition of the pathways leading to activation of the CREB1 inhibitor GSK3<italic>&#x3b2;</italic>, and highlights that GSK3<italic>&#x3b2;</italic> is necessary for the TLR4-mediated M1 inflammatory response, as suggested before Xia et&#xa0;al. (<xref ref-type="bibr" rid="B32">32</xref>)Ko and Lee (<xref ref-type="bibr" rid="B46">46</xref>).</p>
</sec>
<sec id="s3_4">
<label>3.4</label>
<title>Induction of phagocytosis by IgG-immune complexes and IL-4 effect</title>
<p>The binding of IgG-antigen immune complexes (IC) to Fc receptors induces strong phagocytosis, antigen presentation capabilities and production of pro-inflammatory cytokines in monocytes (<xref ref-type="bibr" rid="B47">47</xref>&#x2013;<xref ref-type="bibr" rid="B49">49</xref>). <xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8A</bold></xref> shows the result of modelling the addition of IgG-antigen immune complexes to LPS+IFN-<italic>&#x3b3;</italic>-activated monocytes. Besides the induction of all the pro-inflammatory cytokines, signaling through the Fc<italic>&#x3b3;</italic> receptor induces the promotion of phagocytosis, antigen processing, and MHC class II presentation through the Syk-VAV-Rac pathway (<xref ref-type="bibr" rid="B47">47</xref>&#x2013;<xref ref-type="bibr" rid="B49">49</xref>). As shown above, the presence of IFN-<italic>&#x3b3;</italic> keeps CREB1 inactive and so NF-<italic>&#x3ba;</italic>B is active.</p>
<p><xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8B</bold></xref> shows that the input of IL-4 to the LPS+IFN-<italic>&#x3b3;</italic>+IgG (IC) condition, blocks the NF-<italic>&#x3ba;</italic>B function and TNF-<italic>&#x3b1;</italic> synthesis, while the activation of JMJD3 promotes the function of the IRF4 transcription factor. IRF4 inhibits STAT5, thus inhibiting IL-12 secretion; however, a transient production of this cytokine is still supported by STAT1, NF-<italic>&#x3ba;</italic>B, and AP-1 activities (<xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8B</bold></xref>). IL-1 is not produced, as described (<xref ref-type="bibr" rid="B50">50</xref>). The production of IL-10 is induced by IL-4 respect to the previous condition and the metabolism is shifted to oxidative phosphorylation. As a whole, IL-4 leads to an M2 profile. The results of the modelling agree with the notion that IL-4 can counteract the stimulation by LPS, IgG-immune complexes, and IFN-<italic>&#x3b3;</italic> in monocytes (<xref ref-type="bibr" rid="B51">51</xref>&#x2013;<xref ref-type="bibr" rid="B53">53</xref>), whereas the phagocytosis and antigen processing capabilities are maintained.</p>
<p>Intracellular TLR7 and TLR8 recognize ssRNA and signal though the TRAF3 and MyD88 elements. Whereas signals downstream MyD88 induce the production of pro-inflammatory cytokines, TRAF3 induces the activity of interferon regulatory factors 3 and 7 (IRF3 and IRF7), which promote the production of type I interferons (IFN<italic>&#x3b1;</italic> and IFN<italic>&#x3b2;</italic>), essential components of the anti-viral response (<xref ref-type="bibr" rid="B54">54</xref>). These rules were included in the model (<xref ref-type="table" rid="T2"><bold>Table 2</bold></xref>) and the effect of ssRNA stimulation was analyzed. Results showed that ssRNA-only stimulation induces a glycolytic metabolism and only a transient expression of NF-<italic>&#x3ba;</italic>B and IRF-3 (see the interactive program <italic>Final monocyte network.ipynb</italic> in the <italic>Google Colab</italic> application). IFN-<italic>&#x3b3;</italic> greatly potentiate the M1 pro-inflammatory profile (<xref ref-type="bibr" rid="B55">55</xref>&#x2013;<xref ref-type="bibr" rid="B57">57</xref>), with a stable induction of NF-<italic>&#x3ba;</italic>B and IRF3. IgG (IC)) added phagocytosis and antigen presentation activities to the ssRNA+IFN-<italic>&#x3b3;</italic> situation (<xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8C</bold></xref>). The expression of M2 markers was not obtained. Therefore, the model integrates the view that IFN-<italic>&#x3b3;</italic> supports the production of pro-inflammatory cytokines, whereas IgG immune complexes induce phagocytosis and antigen presentation capabilities during the ssRNA+IFN-<italic>&#x3b3;</italic> response. As in the case shown in <xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8B</bold></xref>, the addition of IL-4 produces the inhibition of NF-<italic>&#x3ba;</italic>B, a transient production of IL-12, and the expression of M2 markers. In addition, the expression of IRF3 is inhibited (<xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8D</bold></xref>).</p>
</sec>
<sec id="s3_5">
<label>3.5</label>
<title>Robustness of the macrophage differentiation process</title>
<p>Stochastic models have been instrumental in exploring system stability in the face of fluctuations arising from random variations of the exogenous cell microenvironment or inner signaling pathways. A robustness index, <italic>R</italic>, was calculated for perturbations of the initial levels of phenotype-inducing microenvironments: M1 (LPS and IFNG-<italic>&#x3b3;</italic>), M2a (IL-4), M2b (LPS and IL-1<italic>&#x3b2;</italic>) and M2c (IL-10). It may be observed that up to perturbation amplitudes <italic>&#x3f5;<sub>R</sub></italic>&#x223c; 20%, the phenotype differentiation processes show a strong robustness with respect to initial-condition variations. In the case with <italic>&#x3f5;<sub>R</sub></italic>&#x223c; 30%, only the robustness of the M2b phenotype is significantly reduced (<xref ref-type="table" rid="T3"><bold>Table 3</bold></xref>). A similar analysis performed for the <italic>&#x3b2;</italic> parameter indicated that up to <italic>&#x3f5;<sub>R</sub></italic>&#x223c; 30%, the robustness index <italic>R</italic> &#x2265; 0.98 in all the above mentioned cases. As an alternative stability proof, we translated the deterministic model into a stochastic scheme (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref> and 2.3.2) to explore the effect of intrinsic noise on the system dynamics (<xref ref-type="bibr" rid="B13">13</xref>, <xref ref-type="bibr" rid="B28">28</xref>). Different levels of noise were introduced into the equations as described in Section 2.3.2, and 1,000 iterations were performed to obtain an average percentage of differentiated cells under each tested condition. <xref ref-type="fig" rid="f10"><bold>Figure&#xa0;10</bold></xref> shows differentiation efficiencies (<italic>&#x3f5;<sub>D</sub></italic>) under M1, M2a, M2b and M2c input conditions, considering 0% to 50% noise. It can be seen that the differentiation process of all phenotypes is very robust, with <italic>&#x3f5;<sub>D</sub></italic> &#x2265; 0.9 (90%), except for M2c cells for noise levels higher than 30 %, where <italic>&#x3f5;<sub>D</sub></italic> exhibits a drastic reduction.</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>Robustness index, <italic>R</italic>, for perturbation of initial levels of phenotype-inducing microenvironments: M1 (LPS and IFNG-<italic>&#x3b3;</italic>), M2a (IL-4), M2b (LPS and IL-1<italic>&#x3b2;</italic>) and M2c (IL-10).</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" colspan="5" align="center"><italic>R</italic></th>
</tr>
<tr>
<th valign="middle" align="center"><italic>&#x3f5;<sub>R</sub></italic> (%)</th>
<th valign="middle" align="center">M1</th>
<th valign="middle" align="center">M2a</th>
<th valign="middle" align="center">M2b</th>
<th valign="middle" align="center">M2c</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="center">10</td>
<td valign="middle" align="center">0.98</td>
<td valign="middle" align="center">0.98</td>
<td valign="middle" align="center">0.99</td>
<td valign="middle" align="center">0.98</td>
</tr>
<tr>
<td valign="middle" align="center">20</td>
<td valign="middle" align="center">0.96</td>
<td valign="middle" align="center">0.97</td>
<td valign="middle" align="center">0.97</td>
<td valign="middle" align="center">0.96</td>
</tr>
<tr>
<td valign="middle" align="center">30</td>
<td valign="middle" align="center">0.89</td>
<td valign="middle" align="center">0.95</td>
<td valign="middle" align="center">0.66</td>
<td valign="middle" align="center">0.95</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>It may be observed that up to perturbation amplitudes <italic>&#x3f5;<sub>R</sub></italic>&#x223c; 20%, the phenotype differentiation processes shows a strong robustness with respect to initial-condition variations. In the case with <italic>&#x3f5;<sub>R</sub></italic>&#x223c; 30%, only the M2b phenotype is significantly affected.</p></fn>
</table-wrap-foot>
</table-wrap>
<fig id="f10" position="float">
<label>Figure&#xa0;10</label>
<caption>
<p>Effect of randomly distributed values of microenvironmental and cell nodes (stochastic noise) on macrophage differentiation efficiency under M1, M2a, M2b, and M2c input conditions. was calculated after 1,000 iterations. M1, M2a, and M2b remain stable around 100%. M2c declines significantly after 30% noise level. Error bars indicate standard deviation.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-16-1639005-g010.tif">
<alt-text content-type="machine-generated">Line graph showing differentiation eficiency percentage against noise level for M1 (blue), M2a (orange), M2b (green), and M2c (red) phenotypes. M1, M2a, and M2b remain stable around 100%. M2c declines significantly after 30% noise level. Error bars indicate variability after 1000 iterations.</alt-text>
</graphic></fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<label>4</label>
<title>Discussion</title>
<p>Studies using single-cell RNA sequencing of monocytes and macrophages from different organs in physiological and pathological states (<xref ref-type="bibr" rid="B58">58</xref>) demonstrate that macrophage functional states are very diverse (<xref ref-type="fig" rid="f1"><bold>Figure&#xa0;1</bold></xref>). The present model attempts to approach this notion, integrating signaling pathways from a number of surface receptors. The network topology highlights the significant convergence toward NF<italic>&#x3ba;</italic>B from various independently acting elements, a characteristic reflected in the NF<italic>&#x3ba;</italic>B Boolean rule (<xref ref-type="table" rid="T2"><bold>Table&#xa0;2</bold></xref>). Other transcription factors such as AP-1, CREB1, IRF3, IRF4, and IRF7 have more specific activation requirements and can act in concert with NF<italic>&#x3ba;</italic>B and AP-1 to amplify the inflammatory response (<xref ref-type="bibr" rid="B18">18</xref>, <xref ref-type="bibr" rid="B59">59</xref>, <xref ref-type="bibr" rid="B60">60</xref>).</p>
<p>The anti-inflammatory role of CREB1 through the inhibition of NF-<italic>&#x3ba;</italic>B was incorporated in the model, as well as the constitutive expression of the CREB1 inhibitor GSK3<italic>&#x3b2;</italic>. The model simulated the pathway of inhibition of CREB1 by IFN-<italic>&#x3b3;</italic>, which involves four consecutive inhibitory interactions (see Section 2.3) and allowed to assess the role of IFN-&#x3b3; and the requirement of GSK3&#x3b2; activity in the potentiation of the NF<italic>&#x3ba;</italic>B-mediated inflammatory response (<xref ref-type="bibr" rid="B32">32</xref>). The transcription factor regulator TRAF3 is also a convergence point for signals initiated by Toll-like receptors. Likewise, the Syk kinase is a critical component where multiple signaling pathways converge, particularly those derived from phagocytosis receptors. In addition, the AMPK module allows the simulation of the pivotal role of metabolism in the phenotypic modulation of macrophages. Thus, the model formally exemplifies how key regulatory elements serve as hubs for the convergence of intricate signals during cellular responses.</p>
<p>The network dynamics reproduced the role of IL-4 and IL-10 in macrophage differentiation towards the M2a and M2b phenotypes through pathways converging in NF-<italic>&#x3ba;</italic>B inhibition (<xref ref-type="fig" rid="f6"><bold>Figure&#xa0;6</bold></xref>). So, the network successfully integrated signals modulating the activity of NF-<italic>&#x3ba;</italic>B (<xref ref-type="bibr" rid="B61">61</xref>, <xref ref-type="bibr" rid="B62">62</xref>). Additional nodes regulating NF-<italic>&#x3ba;</italic>B may be incorporated in the model to fully capture its intricate function (work in progress).</p>
<p>Simulations allowed the integration of the TLR7 activation by ssRNA with the pro-inflammatory effect of IFN-<italic>&#x3b3;</italic>, leading to a robust M1 differentiation, similar to that induced by the TLR4-LPS combination; IgG immune complexes (IC) added phagocytosis to the whole response (<xref ref-type="fig" rid="f8"><bold>Figure&#xa0;8C</bold></xref>). The mathematical model may support the interpretation of experimental results regarding the effect of ssRNA, particularly when additional stimulus, as phorbol 12-myristate 13-acetate (PMA), a strong stimulator of PKC (and thus, of NF-<italic>&#x3ba;</italic>B), are used to promote macrophage differentiation (<xref ref-type="bibr" rid="B63">63</xref>). The model predicts that stimulation by ssRNA in the absence of PMA would induce a transient production of TNF-<italic>&#x3b1;</italic> and IL-1<italic>&#x3b2;</italic> due to transient NF-<italic>&#x3ba;</italic>B and IRF7 activities. Induction of stable expression of pro-inflammatory cytokines by ssRNA can be achieved in the presence of IFN-<italic>&#x3b3;</italic> in the absence of PMA (this result can be achieved using the interactive program <italic>Final monocyte network.ipynb</italic> in the <italic>Google Colab</italic> web site).</p>
<p>Robustness analysis support the confidence of the model results and suggest that the macrophage functional network topology exhibits a strong stability under microenvironment and endogenous perturbations (&#x223c; 90% for noise levels <italic>Q</italic> = 20%). In contrast, a similar analysis for the differentiation efficiency of a CD4 T-cells network exhibited a greater sensitivity to noise (&#x223c; 60%, for <italic>Q</italic> = 20%) (<xref ref-type="bibr" rid="B28">28</xref>). So, our modeling strongly suggests that the network topology of intracellular macrophage signaling involves a structure less sensitive to random variations than the one of lymphocytes, perhaps due to natural selection mechanisms.</p>
<p>In summary, the mathematical model put forth here manages to reproduce the macrophage properties in varied initial conditions, underscoring their functional complexity and adaptability to the microenvironment. It turns out that the development of fully-polarized phenotypes arise under specific microenvironmental conditions. In general, diverse combinations and levels of exogenous agents lead to mixed-polarized expressions (M1/M2) (<xref ref-type="fig" rid="f7"><bold>Figure&#xa0;7</bold></xref>), including modifications of metabolic processes. This is in line with the proposal of Palma et&#xa0;al. (<xref ref-type="bibr" rid="B9">9</xref>) concerning the possibility of a continuum of macrophage polarization transitions among M1 and M2 subtypes.</p>
<sec id="s4_1">
<label>4.1</label>
<title>Implications and future directions</title>
<p>The model captures the dynamics of macrophage functional polarization in agreement with experimental observations, providing a solid framework for the comprehensive description of monocyte behavior. Further work should include interactions improving the prediction of functional features, like those driven by metabolic changes mediated by mTORC2, cytoskeletal dynamics and chemokine production. Other relevant functions of GSK3<italic>&#x3b2;</italic> in addition to inhibition of CREB1 (<xref ref-type="bibr" rid="B46">46</xref>) may be considered. The stimulatory effect of NF-<italic>&#x3ba;</italic>B on the expression of phagocytosis receptors different from Fc<italic>&#x3b3;</italic>R, like Dectin and the mannose receptor are incorporated in the model; mathematical simulation of signaling from them is a work in progress.</p>
<p>The modular structure of the monocyte/macrophage network allows its integration with regulatory networks pertaining to other cells of the immune system, or to tissues interacting with them through soluble factors. Work in progress involves connecting the present macrophage network with a CD4 T cell lymphocyte differentiation network (<xref ref-type="bibr" rid="B26">26</xref>) with the aim of simulating the immune response to respiratory infections (<xref ref-type="bibr" rid="B64">64</xref>), and that of diseases with chronic inflammatory origin, such as type 2 diabetes (<xref ref-type="bibr" rid="B25">25</xref>).</p>
</sec>
</sec>
</body>
<back>
<sec id="s5" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>DM-M: Conceptualization, Data curation, Investigation, Formal Analysis, Methodology, Software, Writing &#x2013; original draft. IA: Investigation, Data curation, Validation, Writing &#x2013; review &amp; editing. LC: Investigation, Writing &#x2013; review &amp; editing. LJ-A: Investigation, Validation, Writing &#x2013; review &amp; editing. AC-L: Investigation, Data curation, Writing &#x2013; review &amp; editing. JZ: Investigation, Validation, Writing &#x2013; review &amp; editing. CV: Investigation, Conceptualization, Formal Analysis, Funding acquisition, Methodology, Validation, Writing &#x2013; review &amp; editing, Writing &#x2013; original draft. LH: Data curation, Investigation, Conceptualization, Funding acquisition, Project administration, Supervision, Validation, Writing &#x2013; review &amp; editing, Writing &#x2013; original draft.</p></sec>
<ack>
<title>Acknowledgments</title>
<p>DM-M, LH and CV acknowledge support from Centro de Ciencias de la Complejidad (C3), Universidad Nacional Aut&#xf3;noma de M&#xe9;xico.</p>
</ack>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
<p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></sec>
<sec id="s9" sec-type="ai-statement">
<title>Generative AI statement</title>
<p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p></sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec>
<sec id="s11" sec-type="supplementary-material">
<title>Supplementary material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2025.1639005/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2025.1639005/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="DataSheet1.pdf" id="SM1" mimetype="application/pdf"/></sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ginhoux</surname> <given-names>F</given-names></name>
<name><surname>Jung</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>Monocytes and macrophages: developmental pathways and tissue homeostasis</article-title>. <source>Nat Rev Immunol</source>. (<year>2014</year>) <volume>14</volume>:<fpage>392</fpage>&#x2013;<lpage>404</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri3671</pub-id>, PMID: <pub-id pub-id-type="pmid">24854589</pub-id>
</mixed-citation>
</ref>
<ref id="B2">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Geissmann</surname> <given-names>F</given-names></name>
<name><surname>Manz</surname> <given-names>MG</given-names></name>
<name><surname>Jung</surname> <given-names>S</given-names></name>
<name><surname>Sieweke</surname> <given-names>MH</given-names></name>
<name><surname>Merad</surname> <given-names>M</given-names></name>
<name><surname>Ley</surname> <given-names>K</given-names></name>
</person-group>. 
<article-title>Development of monocytes, macrophages, and dendritic cells</article-title>. <source>Science</source>. (<year>2010</year>) <volume>327</volume>:<page-range>656&#x2013;61</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/science.1178331</pub-id>, PMID: <pub-id pub-id-type="pmid">20133564</pub-id>
</mixed-citation>
</ref>
<ref id="B3">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mantovani</surname> <given-names>A</given-names></name>
<name><surname>Biswas</surname> <given-names>SK</given-names></name>
<name><surname>Galdiero</surname> <given-names>MR</given-names></name>
<name><surname>Sica</surname> <given-names>A</given-names></name>
<name><surname>Locati</surname> <given-names>M</given-names></name>
</person-group>. 
<article-title>Macrophage plasticity and polarization in tissue repair and remodelling</article-title>. <source>J Pathol</source>. (<year>2013</year>) <volume>229</volume>:<page-range>176&#x2013;85</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/path.4133</pub-id>, PMID: <pub-id pub-id-type="pmid">23096265</pub-id>
</mixed-citation>
</ref>
<ref id="B4">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Biswas</surname> <given-names>SK</given-names></name>
<name><surname>Mantovani</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm</article-title>. <source>Nat Immunol</source>. (<year>2010</year>) <volume>11</volume>:<page-range>889&#x2013;96</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.1937</pub-id>, PMID: <pub-id pub-id-type="pmid">20856220</pub-id>
</mixed-citation>
</ref>
<ref id="B5">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Orekhov</surname> <given-names>AN</given-names></name>
<name><surname>Orekhova</surname> <given-names>VA</given-names></name>
<name><surname>Nikiforov</surname> <given-names>NG</given-names></name>
<name><surname>Myasoedova</surname> <given-names>VA</given-names></name>
<name><surname>Grechko</surname> <given-names>AV</given-names></name>
<name><surname>Romanenko</surname> <given-names>EB</given-names></name>
<etal/>
</person-group>. 
<article-title>Monocyte differentiation and macrophage polarization</article-title>. <source>Vessel Plus</source>. (<year>2019</year>) <volume>3</volume>:<elocation-id>10</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.20517/2574-1209.2019.04</pub-id>
</mixed-citation>
</ref>
<ref id="B6">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Italiani</surname> <given-names>P</given-names></name>
<name><surname>Boraschi</surname> <given-names>D</given-names></name>
</person-group>. 
<article-title>From monocytes to m1/m2 macrophages: Phenotypical vs. functional differentiation</article-title>. <source>Front Immunol</source>. (<year>2014</year>) <volume>5</volume>:<elocation-id>514</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2014.00514</pub-id>, PMID: <pub-id pub-id-type="pmid">25368618</pub-id>
</mixed-citation>
</ref>
<ref id="B7">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kelly</surname> <given-names>B</given-names></name>
<name><surname>O&#x2019;Neill</surname> <given-names>LA</given-names></name>
</person-group>. 
<article-title>Metabolic reprogramming in macrophages and dendritic cells in innate immunity</article-title>. <source>Cell Res</source>. (<year>2015</year>) <volume>25</volume>:<page-range>771&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cr.2015.68</pub-id>, PMID: <pub-id pub-id-type="pmid">26045163</pub-id>
</mixed-citation>
</ref>
<ref id="B8">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>O&#x2019;Neill</surname> <given-names>LA</given-names></name>
<name><surname>Pearce</surname> <given-names>EJ</given-names></name>
</person-group>. 
<article-title>Immunometabolism governs dendritic cell and macrophage function</article-title>. <source>J Exp Med</source>. (<year>2016</year>) <volume>213</volume>:<fpage>15</fpage>&#x2013;<lpage>23</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.20151570</pub-id>, PMID: <pub-id pub-id-type="pmid">26694970</pub-id>
</mixed-citation>
</ref>
<ref id="B9">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Palma</surname> <given-names>A</given-names></name>
<name><surname>Jarrah</surname> <given-names>AS</given-names></name>
<name><surname>Tieri</surname> <given-names>P</given-names></name>
<name><surname>Cesareni1</surname> <given-names>G</given-names></name>
<name><surname>Castiglione</surname> <given-names>F</given-names></name>
</person-group>. 
<article-title>Gene regulatory network modeling of macrophage differentiation corroborates the continuum hypothesis of polarization states</article-title>. <source>Front Physiol</source>. (<year>2018</year>) <volume>9</volume>:<elocation-id>1659</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fphys.2018.01659</pub-id>, PMID: <pub-id pub-id-type="pmid">30546316</pub-id>
</mixed-citation>
</ref>
<ref id="B10">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sobie</surname> <given-names>EA</given-names></name>
<name><surname>Lee</surname> <given-names>Y-S</given-names></name>
<name><surname>Jenkins</surname> <given-names>SL</given-names></name>
<name><surname>Iyengar</surname> <given-names>R</given-names></name>
</person-group>. 
<article-title>Systems biology&#x2014;biomedical modeling</article-title>. <source>Sci Signaling</source>. (<year>2011</year>) <volume>4</volume>:<page-range>tr2&#x2013;2</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1126/scisignal.2001989</pub-id>, PMID: <pub-id pub-id-type="pmid">21917716</pub-id>
</mixed-citation>
</ref>
<ref id="B11">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Albert</surname> <given-names>I</given-names></name>
<name><surname>Thakar</surname> <given-names>J</given-names></name>
<name><surname>Li</surname> <given-names>S</given-names></name>
<name><surname>Zhang</surname> <given-names>R</given-names></name>
<name><surname>Albert</surname> <given-names>R</given-names></name>
</person-group>. 
<article-title>Boolean network simulations for life scientists</article-title>. <source>Source Code Biol Med</source>. (<year>2008</year>) <volume>3</volume>:<fpage>1</fpage>&#x2013;<lpage>7</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1751-0473-3-16</pub-id>, PMID: <pub-id pub-id-type="pmid">19014577</pub-id>
</mixed-citation>
</ref>
<ref id="B12">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Albert</surname> <given-names>R</given-names></name>
<name><surname>Thakar</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>Boolean modeling: A logic-based dynamic approach for understanding signaling and regulatory networks and for making useful predictions</article-title>. <source>WIREs Syst Biol Med</source>. (<year>2014</year>) <volume>6</volume>:<page-range>353&#x2013;69</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/wsbm.1273</pub-id>, PMID: <pub-id pub-id-type="pmid">25269159</pub-id>
</mixed-citation>
</ref>
<ref id="B13">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Villarreal</surname> <given-names>C</given-names></name>
<name><surname>Padilla-Longoria</surname> <given-names>P</given-names></name>
<name><surname>Alvarez-Buylla</surname> <given-names>E</given-names></name>
</person-group>. 
<article-title>General theory of genotype to phenotype mapping: Derivation of epigenetic landscapes from n-node complex gene regulatory networks</article-title>. <source>Phys Rev Lett</source>. (<year>2012</year>) <volume>109</volume>:<fpage>1</fpage>&#x2013;<lpage>5</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1103/PhysRevLett.109.118102</pub-id>, PMID: <pub-id pub-id-type="pmid">23005679</pub-id>
</mixed-citation>
</ref>
<ref id="B14">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Enciso</surname> <given-names>J</given-names></name>
<name><surname>Pelayo</surname> <given-names>R</given-names></name>
<name><surname>Villarreal</surname> <given-names>C</given-names></name>
</person-group>. 
<article-title>From discrete to continuous modeling of lymphocyte develoment and plasticity in chronic diseases</article-title>. <source>Front Immunol</source>. (<year>2019</year>) <volume>10</volume>:<elocation-id>1927</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2019.01927</pub-id>, PMID: <pub-id pub-id-type="pmid">31481957</pub-id>
</mixed-citation>
</ref>
<ref id="B15">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Akira</surname> <given-names>S</given-names></name>
<name><surname>Takeda</surname> <given-names>K</given-names></name>
</person-group>. 
<article-title>Toll-like receptor signalling</article-title>. <source>Nat Rev Immunol</source>. (<year>2004</year>) <volume>4</volume>:<fpage>499</fpage>&#x2013;<lpage>511</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri1391</pub-id>, PMID: <pub-id pub-id-type="pmid">15229469</pub-id>
</mixed-citation>
</ref>
<ref id="B16">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kawai</surname> <given-names>T</given-names></name>
<name><surname>Akira</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>The role of pattern-recognition receptors in innate immunity: update on toll-like receptors</article-title>. <source>Nat Immunol</source>. (<year>2010</year>) <volume>11</volume>:<page-range>373&#x2013;84</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/ni.1863</pub-id>, PMID: <pub-id pub-id-type="pmid">20404851</pub-id>
</mixed-citation>
</ref>
<ref id="B17">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Al-Roub</surname> <given-names>A</given-names></name>
<name><surname>Madhoun</surname> <given-names>AA</given-names></name>
<name><surname>Akhter</surname> <given-names>N</given-names></name>
<name><surname>Thomas</surname> <given-names>R</given-names></name>
<name><surname>Miranda</surname> <given-names>L</given-names></name>
<name><surname>Jacob</surname> <given-names>T</given-names></name>
<etal/>
</person-group>. 
<article-title>Il-1 and tnf cooperativity in regulating il-6 expression in adipocytes depends on creb binding and h3k14 acetylation</article-title>. <source>Cells</source>. (<year>2021</year>) <volume>10</volume>:<elocation-id>3228</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/cells10113228</pub-id>, PMID: <pub-id pub-id-type="pmid">34831450</pub-id>
</mixed-citation>
</ref>
<ref id="B18">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wen</surname> <given-names>AY</given-names></name>
<name><surname>Sakamoto</surname> <given-names>KM</given-names></name>
<name><surname>Miller</surname> <given-names>LS</given-names></name>
</person-group>. 
<article-title>The role of the transcription factor creb in immune function</article-title>. <source>J Immunol (Baltimore Md</source>. (<year>2010</year>) <volume>185</volume>:<page-range>6413&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.1001829</pub-id>, PMID: <pub-id pub-id-type="pmid">21084670</pub-id>
</mixed-citation>
</ref>
<ref id="B19">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gonz&#xe1;lez</surname> <given-names>ML</given-names></name>
<name><surname>Oosterhoff</surname> <given-names>D</given-names></name>
<name><surname>Lindenberg</surname> <given-names>JJ</given-names></name>
<name><surname>Milenova</surname> <given-names>I</given-names></name>
<name><surname>Lougheed</surname> <given-names>SM</given-names></name>
<name><surname>Marti&#xe1;&#xf1;ez</surname> <given-names>T</given-names></name>
<etal/>
</person-group>. 
<article-title>Constitutively active gsk3 as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression</article-title>. <source>OncoImmunology</source>. (<year>2019</year>) <volume>8</volume>:<fpage>e1631119</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1080/2162402X.2019.1631119</pub-id>, PMID: <pub-id pub-id-type="pmid">31646076</pub-id>
</mixed-citation>
</ref>
<ref id="B20">
<label>20</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author">
<name><surname>Waddington</surname> <given-names>CH</given-names></name>
</person-group>. <source>The strategy of the genes</source>. <publisher-loc>London</publisher-loc>: 
<publisher-name>George Allen Unwin</publisher-name> (<year>1957</year>).
</mixed-citation>
</ref>
<ref id="B21">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Glass</surname> <given-names>L</given-names></name>
<name><surname>Kauffman</surname> <given-names>SA</given-names></name>
</person-group>. 
<article-title>The logical analysis of continuous, non-linear biochemical control networks</article-title>. <source>Theor Biol</source>. (<year>1973</year>) <volume>39</volume>:<page-range>103&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/0022-5193(73)90208-7</pub-id>, PMID: <pub-id pub-id-type="pmid">4741704</pub-id>
</mixed-citation>
</ref>
<ref id="B22">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Glass</surname> <given-names>L</given-names></name>
</person-group>. 
<article-title>Classification of biological networks by their qualitative dynamics</article-title>. <source>J Theor Biol</source>. (<year>1975</year>) <volume>54</volume>:<fpage>85</fpage>&#x2013;<lpage>107</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0022-5193(75)80056-7</pub-id>, PMID: <pub-id pub-id-type="pmid">1202295</pub-id>
</mixed-citation>
</ref>
<ref id="B23">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zadeh</surname> <given-names>L</given-names></name>
</person-group>. 
<article-title>Fuzzy sets</article-title>. <source>Inf Control</source>. (<year>1965</year>) <volume>8</volume>:<fpage>228</fpage>&#x2013;<lpage>353</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S0019-9958(65)90241-X</pub-id>
</mixed-citation>
</ref>
<ref id="B24">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mendoza</surname> <given-names>L</given-names></name>
<name><surname>Xenarios</surname> <given-names>I</given-names></name>
</person-group>. 
<article-title>A method for the generation of standardized qualitative dynamical systems of regulatory networks</article-title>. <source>Theor Biol Med Modeling</source>. (<year>2006</year>) <volume>3</volume>:<fpage>1</fpage>&#x2013;<lpage>18</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/1742-4682-3-13</pub-id>, PMID: <pub-id pub-id-type="pmid">16542429</pub-id>
</mixed-citation>
</ref>
<ref id="B25">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Barrera</surname> <given-names>M</given-names></name>
<name><surname>Hiriart</surname> <given-names>M</given-names></name>
<name><surname>Cocho</surname> <given-names>G</given-names></name>
<name><surname>Villarreal</surname> <given-names>C</given-names></name>
</person-group>. 
<article-title>Type 2 diabetes progression: A regulatory network approach</article-title>. <source>Chaos: Interdiscip J Nonlinear Sci</source>. (<year>2020</year>) <volume>30</volume>:<fpage>093132</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1063/5.0011125</pub-id>, PMID: <pub-id pub-id-type="pmid">33003944</pub-id>
</mixed-citation>
</ref>
<ref id="B26">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mart&#xed;nez-M&#xe9;ndez</surname> <given-names>D</given-names></name>
<name><surname>Mendoza</surname> <given-names>L</given-names></name>
<name><surname>Villarreal</surname> <given-names>C</given-names></name>
<name><surname>Huerta</surname> <given-names>L</given-names></name>
</person-group>. 
<article-title>Continuous modeling of t cd4 lymphocyte activation and function</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>743559</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.743559</pub-id>, PMID: <pub-id pub-id-type="pmid">34804023</pub-id>
</mixed-citation>
</ref>
<ref id="B27">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mart&#xed;nez-M&#xe9;ndez</surname> <given-names>D</given-names></name>
<name><surname>Huerta</surname> <given-names>L</given-names></name>
<name><surname>Villarreal</surname> <given-names>C</given-names></name>
</person-group>. 
<article-title>Modeling the effect of environmental cytokines, nutrient conditions and hypoxia on cd4+ t cell differentiation</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>962175</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.962175</pub-id>, PMID: <pub-id pub-id-type="pmid">36211418</pub-id>
</mixed-citation>
</ref>
<ref id="B28">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mart&#xed;nez-M&#xe9;ndez</surname> <given-names>D</given-names></name>
<name><surname>Villarreal</surname> <given-names>C</given-names></name>
<name><surname>Huerta</surname> <given-names>L</given-names></name>
</person-group>. 
<article-title>Modeling uncertainty: the impact of noise in t cell differentiation</article-title>. <source>Front Syst Biol</source>. (<year>2024</year>) <volume>4</volume>:<elocation-id>1412931</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fsysb.2024.1412931</pub-id>, PMID: <pub-id pub-id-type="pmid">40809135</pub-id>
</mixed-citation>
</ref>
<ref id="B29">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ye</surname> <given-names>J</given-names></name>
<name><surname>Li</surname> <given-names>A</given-names></name>
<name><surname>Zhai</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>A measure of concentration robustness in a biochemical reaction network and its application on system identification</article-title>. <source>Appl Math Model</source>. (<year>2018</year>) <volume>58</volume>:<page-range>270&#x2013;80</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.apm.2017.07.026</pub-id>
</mixed-citation>
</ref>
<ref id="B30">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>De Arellano</surname> <given-names>MG</given-names></name>
<name><surname>Piedra-Quintero</surname> <given-names>ZL</given-names></name>
<name><surname>Tsichlis</surname> <given-names>PN</given-names></name>
</person-group>. 
<article-title>Akt isoforms in the immune system</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>2022.990874</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.990874</pub-id>, PMID: <pub-id pub-id-type="pmid">36081513</pub-id>
</mixed-citation>
</ref>
<ref id="B31">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Arranz</surname> <given-names>A</given-names></name>
<name><surname>Doxaki</surname> <given-names>C</given-names></name>
<name><surname>Vergadi</surname> <given-names>E</given-names></name>
<name><surname>Vaporidi</surname> <given-names>K</given-names></name>
<name><surname>Lagoudaki</surname> <given-names>ED</given-names></name>
<name><surname>Ieronymaki</surname> <given-names>E</given-names></name>
</person-group>. 
<article-title>Akt1 and akt2 protein kinases differentially contribute to macrophage polarization</article-title>. <source>Proc Natl Acad Sci U.S.A</source>. (<year>2012</year>) <volume>109</volume>:<page-range>9517&#x2013;22</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.1119038109</pub-id>, PMID: <pub-id pub-id-type="pmid">22647600</pub-id>
</mixed-citation>
</ref>
<ref id="B32">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xia</surname> <given-names>T</given-names></name>
<name><surname>Fu</surname> <given-names>S</given-names></name>
<name><surname>Yang</surname> <given-names>R</given-names></name>
<name><surname>Yang</surname> <given-names>K</given-names></name>
<name><surname>Lei</surname> <given-names>W</given-names></name>
<name><surname>Yang</surname> <given-names>Y</given-names></name>
<etal/>
</person-group>. 
<article-title>Advances in the study of macrophage polarization in inflammatory immune skin diseases</article-title>. <source>J Inflammation</source>. (<year>2023</year>) <volume>20</volume>:<fpage>33</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s12950-023-00360-z</pub-id>, PMID: <pub-id pub-id-type="pmid">37828492</pub-id>
</mixed-citation>
</ref>
<ref id="B33">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gao</surname> <given-names>J</given-names></name>
<name><surname>Liang</surname> <given-names>Y</given-names></name>
<name><surname>Wang</surname> <given-names>L</given-names></name>
</person-group>. 
<article-title>Shaping polarization of tumor-associated macrophages in cancer immunotherapy</article-title>. <source>Front Immunol</source>. (<year>2022</year>) <volume>13</volume>:<elocation-id>888713</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.888713</pub-id>, PMID: <pub-id pub-id-type="pmid">35844605</pub-id>
</mixed-citation>
</ref>
<ref id="B34">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Odegaard</surname> <given-names>JI</given-names></name>
<name><surname>Ricardo-Gonzalez</surname> <given-names>RR</given-names></name>
<name><surname>Goforth</surname> <given-names>MH</given-names></name>
<name><surname>Morel</surname> <given-names>CR</given-names></name>
<name><surname>Subramanian</surname> <given-names>V</given-names></name>
<name><surname>Mukundan</surname> <given-names>L</given-names></name>
<etal/>
</person-group>. 
<article-title>Macrophage-specific ppar controls alternative activation and improves insulin resistance</article-title>. <source>Nature</source>. (<year>2007</year>) <volume>447</volume>:<page-range>1116&#x2013;20</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nature05894</pub-id>, PMID: <pub-id pub-id-type="pmid">17515919</pub-id>
</mixed-citation>
</ref>
<ref id="B35">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Pearce</surname> <given-names>E</given-names></name>
<name><surname>Pearce</surname> <given-names>E</given-names></name>
</person-group>. 
<article-title>Metabolic pathways in immune cell activation and quiescence</article-title>. <source>Immunity</source>. (<year>2013</year>) <volume>38</volume>:<page-range>633&#x2013;43</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2013.04.005</pub-id>, PMID: <pub-id pub-id-type="pmid">23601682</pub-id>
</mixed-citation>
</ref>
<ref id="B36">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mosser</surname> <given-names>DM</given-names></name>
<name><surname>Edwards</surname> <given-names>JP</given-names></name>
</person-group>. 
<article-title>Exploring the full spectrum of macrophage activation</article-title>. <source>Nat Rev Immunol</source>. (<year>2008</year>) <volume>8</volume>:<page-range>958&#x2013;69</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri2448</pub-id>, PMID: <pub-id pub-id-type="pmid">19029990</pub-id>
</mixed-citation>
</ref>
<ref id="B37">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Murray</surname> <given-names>PJ</given-names></name>
<name><surname>Wynn</surname> <given-names>TA</given-names></name>
</person-group>. 
<article-title>Protective and pathogenic functions of macrophage subsets</article-title>. <source>Nat Rev Immunol</source>. (<year>2011</year>) <volume>11</volume>:<page-range>723&#x2013;37</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri3073</pub-id>, PMID: <pub-id pub-id-type="pmid">21997792</pub-id>
</mixed-citation>
</ref>
<ref id="B38">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kaplan</surname> <given-names>MH</given-names></name>
<name><surname>Schindler</surname> <given-names>U</given-names></name>
<name><surname>Smiley</surname> <given-names>ST</given-names></name>
<name><surname>Grusby</surname> <given-names>MJ</given-names></name>
</person-group>. 
<article-title>Stat6 is required for mediating responses to il-4 and for the development of th2 cells</article-title>. <source>Immunity</source>. (<year>1996</year>) <volume>4</volume>:<page-range>313&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/S1074-7613(00)80439-2</pub-id>, PMID: <pub-id pub-id-type="pmid">8624821</pub-id>
</mixed-citation>
</ref>
<ref id="B39">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bi</surname> <given-names>Y</given-names></name>
<name><surname>Chen</surname> <given-names>J</given-names></name>
<name><surname>Hu</surname> <given-names>F</given-names></name>
<name><surname>Liu</surname> <given-names>J</given-names></name>
<name><surname>Li</surname> <given-names>M</given-names></name>
<name><surname>Zhao</surname> <given-names>L</given-names></name>
</person-group>. 
<article-title>M2 macrophages as a potential target for antiatherosclerosis treatment</article-title>. <source>Neural Plasticity</source>. (<year>2019</year>) <volume>2019</volume>:<fpage>1</fpage>&#x2013;<lpage>21</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2019/6724903</pub-id>, PMID: <pub-id pub-id-type="pmid">30923552</pub-id>
</mixed-citation>
</ref>
<ref id="B40">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Moore</surname> <given-names>KW</given-names></name>
<name><surname>De Waal Malefyt</surname> <given-names>R</given-names></name>
<name><surname>Coffman</surname> <given-names>RL</given-names></name>
<name><surname>O&#x2019;Garra</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>Interleukin-10 and the interleukin-10 receptor</article-title>. <source>Annu Rev Immunol</source>. (<year>2001</year>) <volume>19</volume>:<fpage>683</fpage>&#x2013;<lpage>765</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev.immunol.19.1.683</pub-id>, PMID: <pub-id pub-id-type="pmid">11244051</pub-id>
</mixed-citation>
</ref>
<ref id="B41">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhang</surname> <given-names>B</given-names></name>
<name><surname>Du</surname> <given-names>Y</given-names></name>
<name><surname>He</surname> <given-names>Y</given-names></name>
<name><surname>Liu</surname> <given-names>Y</given-names></name>
<name><surname>Zhang</surname> <given-names>G</given-names></name>
<name><surname>Yang</surname> <given-names>C</given-names></name>
<etal/>
</person-group>. 
<article-title>Int-ha induces m2-like macrophage differentiation of human monocytes via tlr4-mir-935 pathway</article-title>. <source>Cancer Immunology Immunotherapy</source>. (<year>2019</year>) <volume>68</volume>:<fpage>189</fpage>&#x2013;<lpage>200</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00262-018-2261-6</pub-id>, PMID: <pub-id pub-id-type="pmid">30341559</pub-id>
</mixed-citation>
</ref>
<ref id="B42">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Xun Wang</surname> <given-names>L</given-names></name>
<name><surname>Xi Zhang</surname> <given-names>S</given-names></name>
<name><surname>Juan Wu</surname> <given-names>H</given-names></name>
<name><surname>lu Rong</surname> <given-names>X</given-names></name>
<name><surname>Guo</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>M2b macrophage polarization and its roles in diseases</article-title>. <source>J Leukocyte Biol</source>. (<year>2019</year>) <volume>106</volume>:<page-range>345&#x2013;58</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/JLB.3RU1018-378RR</pub-id>, PMID: <pub-id pub-id-type="pmid">30576000</pub-id>
</mixed-citation>
</ref>
<ref id="B43">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Vats</surname> <given-names>D</given-names></name>
<name><surname>Mukundan</surname> <given-names>L</given-names></name>
<name><surname>Odegaard</surname> <given-names>JI</given-names></name>
<name><surname>Zhang</surname> <given-names>L</given-names></name>
<name><surname>Smith</surname> <given-names>KL</given-names></name>
<name><surname>Morel</surname> <given-names>CR</given-names></name>
<etal/>
</person-group>. 
<article-title>Oxidative metabolism and pgc-1 attenuate macrophage-mediated inflammation</article-title>. <source>Cell Metab</source>. (<year>2006</year>) <volume>4</volume>:<fpage>13</fpage>&#x2013;<lpage>24</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.cmet.2006.05.011</pub-id>, PMID: <pub-id pub-id-type="pmid">16814729</pub-id>
</mixed-citation>
</ref>
<ref id="B44">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Den Bossche</surname> <given-names>JV</given-names></name>
<name><surname>O&#x2019;Neill</surname> <given-names>LA</given-names></name>
<name><surname>Menon</surname> <given-names>D</given-names></name>
</person-group>. 
<article-title>Macrophage immunometabolism: Where are we (going)</article-title>? <source>Trends Immunol</source>. (<year>2017</year>) <volume>38</volume>:<fpage>395</fpage>&#x2013;<lpage>406</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.it.2017.03.001</pub-id>, PMID: <pub-id pub-id-type="pmid">28396078</pub-id>
</mixed-citation>
</ref>
<ref id="B45">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chowdhury</surname> <given-names>MAR</given-names></name>
<name><surname>An</surname> <given-names>J</given-names></name>
<name><surname>Jeong</surname> <given-names>S</given-names></name>
</person-group>. 
<article-title>The pleiotropic face of creb family transcription factors</article-title>. <source>Molecules Cells</source>. (<year>2023</year>) <volume>46</volume>:<fpage>399</fpage>&#x2013;<lpage>413</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.14348/molcells.2023.2193</pub-id>, PMID: <pub-id pub-id-type="pmid">37013623</pub-id>
</mixed-citation>
</ref>
<ref id="B46">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ko</surname> <given-names>R</given-names></name>
<name><surname>Lee</surname> <given-names>SY</given-names></name>
</person-group>. 
<article-title>Glycogen synthase kinase 3 in toll-like receptor signaling</article-title>. <source>BMB Rep</source>. (<year>2016</year>) <volume>49</volume>:<page-range>305&#x2013;10</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.5483/BMBRep.2016.49.6.059</pub-id>, PMID: <pub-id pub-id-type="pmid">26996345</pub-id>
</mixed-citation>
</ref>
<ref id="B47">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Nimmerjahn</surname> <given-names>F</given-names></name>
<name><surname>Ravetch</surname> <given-names>JV</given-names></name>
</person-group>. 
<article-title>Fcgamma receptors as regulators of immune responses</article-title>. <source>Nat Rev Immunol</source>. (<year>2008</year>) <volume>8</volume>(<issue>1</issue>):<page-range>34&#x2013;47</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri2206</pub-id>, PMID: <pub-id pub-id-type="pmid">18064051</pub-id>
</mixed-citation>
</ref>
<ref id="B48">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bournazos</surname> <given-names>S</given-names></name>
<name><surname>Wang</surname> <given-names>TT</given-names></name>
<name><surname>Ravetch</surname> <given-names>JV</given-names></name>
</person-group>. 
<article-title>The role and function of fc receptors on myeloid cells</article-title>. <source>Microbiol Spectr</source>. (<year>2016</year>) <volume>4</volume>:<elocation-id>6</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/microbiolspec.MCHD-0045-2016</pub-id>, PMID: <pub-id pub-id-type="pmid">28087938</pub-id>
</mixed-citation>
</ref>
<ref id="B49">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Underhill</surname> <given-names>DM</given-names></name>
<name><surname>Goodridge</surname> <given-names>HS</given-names></name>
</person-group>. 
<article-title>Information processing during phagocytosis</article-title>. <source>Nat Rev Immunol</source>. (<year>2012</year>) <volume>12</volume>:<fpage>492</fpage>&#x2013;<lpage>502</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nri3244</pub-id>, PMID: <pub-id pub-id-type="pmid">22699831</pub-id>
</mixed-citation>
</ref>
<ref id="B50">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Donnelly</surname> <given-names>RP</given-names></name>
<name><surname>Fenton</surname> <given-names>MJ</given-names></name>
<name><surname>Finbloom</surname> <given-names>DS</given-names></name>
<name><surname>Gerrard</surname> <given-names>TL</given-names></name>
</person-group>. 
<article-title>Differential regulation of il-1 production in human monocytes by ifn-gamma and il-4</article-title>. <source>J Immunol</source>. (<year>1990</year>) <volume>145</volume>:<page-range>569&#x2013;75</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.4049/jimmunol.145.2.569</pub-id>, PMID: <pub-id pub-id-type="pmid">2114443</pub-id>
</mixed-citation>
</ref>
<ref id="B51">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Paludan</surname></name>
</person-group>. 
<article-title>Interleukin-4 and interferon-: The quintessence of a mutual antagonistic relationship</article-title>. <source>Scandinavian J Immunol</source>. (<year>1998</year>) <volume>48</volume>:<page-range>459&#x2013;68</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1046/j.1365-3083.1998.00435.x</pub-id>, PMID: <pub-id pub-id-type="pmid">9822252</pub-id>
</mixed-citation>
</ref>
<ref id="B52">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mar&#xf3;di</surname> <given-names>L</given-names></name>
<name><surname>Schreiber</surname> <given-names>S</given-names></name>
<name><surname>Anderson</surname> <given-names>DC</given-names></name>
<name><surname>MacDermott</surname> <given-names>RP</given-names></name>
<name><surname>Korchak</surname> <given-names>HM</given-names></name>
<name><surname>Johnston</surname> <given-names>RB</given-names></name>
</person-group>. 
<article-title>Enhancement of macrophage candidacidal activity by interferon-gamma. increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors</article-title>. <source>J Clin Invest</source>. (<year>1993</year>) <volume>91</volume>:<page-range>2596&#x2013;601</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1172/JCI116498</pub-id>, PMID: <pub-id pub-id-type="pmid">8390485</pub-id>
</mixed-citation>
</ref>
<ref id="B53">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mijatovic</surname> <given-names>T</given-names></name>
<name><surname>Kruys</surname> <given-names>V</given-names></name>
<name><surname>Caput</surname> <given-names>D</given-names></name>
<name><surname>DeFrance</surname> <given-names>P</given-names></name>
<name><surname>Huez</surname> <given-names>G</given-names></name>
</person-group>. 
<article-title>Interleukin-4 and -13 inhibit tumor necrosis factor- mrna translational activation in lipopolysaccharide-induced mouse macrophages</article-title>. <source>J Biol Chem</source>. (<year>1997</year>) <volume>272</volume>:<page-range>14394&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1074/jbc.272.22.14394</pub-id>, PMID: <pub-id pub-id-type="pmid">9162077</pub-id>
</mixed-citation>
</ref>
<ref id="B54">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lin</surname> <given-names>M</given-names></name>
<name><surname>Ji</surname> <given-names>X</given-names></name>
<name><surname>Lv</surname> <given-names>Y</given-names></name>
<name><surname>Cui</surname> <given-names>D</given-names></name>
<name><surname>Xie</surname> <given-names>J</given-names></name>
</person-group>. 
<article-title>The roles of traf3 in immune responses</article-title>. <source>Dis Markers</source>. (<year>2023</year>) <volume>2023</volume>:<fpage>1</fpage>&#x2013;<lpage>11</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1155/2023/7787803</pub-id>, PMID: <pub-id pub-id-type="pmid">36845015</pub-id>
</mixed-citation>
</ref>
<ref id="B55">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Martin</surname> <given-names>JH</given-names></name>
<name><surname>Edwards</surname> <given-names>SW</given-names></name>
</person-group>. 
<article-title>Interferon-gamma enhances monocyte cytotoxicity via enhanced reactive oxygen intermediate production. absence of an effect on macrophage cytotoxicity is due to failure to enhance reactive nitrogen intermediate production</article-title>. <source>Immunology</source>. (<year>1994</year>) <volume>81</volume>:<page-range>592&#x2013;7</page-range>., PMID: <pub-id pub-id-type="pmid">8039809</pub-id>
</mixed-citation>
</ref>
<ref id="B56">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mart&#xed;nez-Espinoza</surname> <given-names>I</given-names></name>
<name><surname>Guerrero-Plata</surname> <given-names>A</given-names></name>
</person-group>. 
<article-title>The relevance of tlr8 in viral infections</article-title>. <source>Pathogens</source>. (<year>2022</year>) <volume>11</volume>:<elocation-id>134</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3390/pathogens11020134</pub-id>, PMID: <pub-id pub-id-type="pmid">35215078</pub-id>
</mixed-citation>
</ref>
<ref id="B57">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cervantes</surname> <given-names>JL</given-names></name>
<name><surname>Weinerman</surname> <given-names>B</given-names></name>
<name><surname>Basole</surname> <given-names>C</given-names></name>
<name><surname>Salazar</surname> <given-names>JC</given-names></name>
</person-group>. 
<article-title>Tlr8: the forgotten relative revindicated</article-title>. <source>Cell Mol Immunol</source>. (<year>2012</year>) <volume>9</volume>:<page-range>434&#x2013;8</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/cmi.2012.38</pub-id>, PMID: <pub-id pub-id-type="pmid">23085951</pub-id>
</mixed-citation>
</ref>
<ref id="B58">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mulder</surname> <given-names>K</given-names></name>
<name><surname>Patel</surname> <given-names>AA</given-names></name>
<name><surname>Kong</surname> <given-names>WT</given-names></name>
<name><surname>Piot</surname> <given-names>C</given-names></name>
<name><surname>Halitzki</surname> <given-names>E</given-names></name>
<name><surname>Dunsmore</surname> <given-names>G</given-names></name>
<etal/>
</person-group>. 
<article-title>Cross-tissue single-cell landscape of human monocytes and macrophages in health and disease</article-title>. <source>Immunity</source>. (<year>2021</year>) <volume>54</volume>:<fpage>1883</fpage>&#x2013;<lpage>1900.e5</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.immuni.2021.07.007</pub-id>, PMID: <pub-id pub-id-type="pmid">34331874</pub-id>
</mixed-citation>
</ref>
<ref id="B59">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Tavares</surname> <given-names>LP</given-names></name>
<name><surname>Negreiros-Lima</surname> <given-names>GL</given-names></name>
<name><surname>Lima</surname> <given-names>KM</given-names></name>
<name><surname>Silva</surname> <given-names>PME</given-names></name>
<name><surname>Pinho</surname> <given-names>V</given-names></name>
<name><surname>Teixeira</surname> <given-names>MM</given-names></name>
<etal/>
</person-group>. 
<article-title>Blame the signaling: Role of camp for the resolution of inflammation</article-title>. <source>Pharmacol Res</source>. (<year>2020</year>) <volume>159</volume>:<elocation-id>105030</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.phrs.2020.105030</pub-id>, PMID: <pub-id pub-id-type="pmid">32562817</pub-id>
</mixed-citation>
</ref>
<ref id="B60">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Elcombe</surname> <given-names>SE</given-names></name>
<name><surname>Naqvi</surname> <given-names>S</given-names></name>
<name><surname>Bosch</surname> <given-names>MWMVD.</given-names></name>
<name><surname>MacKenzie</surname> <given-names>KF</given-names></name>
<name><surname>Cianfanelli</surname> <given-names>F</given-names></name>
<name><surname>Brown</surname> <given-names>GD</given-names></name>
<etal/>
</person-group>. 
<article-title>Dectin-1 regulates il-10 production via a msk1/2 and creb dependent pathway and promotes the induction of regulatory macrophage markers</article-title>. <source>PloS One</source>. (<year>2013</year>) <volume>8</volume>:<fpage>e60086</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.pone.0060086</pub-id>, PMID: <pub-id pub-id-type="pmid">23533666</pub-id>
</mixed-citation>
</ref>
<ref id="B61">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mussbacher</surname> <given-names>M</given-names></name>
<name><surname>Derler</surname> <given-names>M</given-names></name>
<name><surname>Bas&#xed;lio</surname> <given-names>J</given-names></name>
<name><surname>Schmid</surname> <given-names>JA</given-names></name>
</person-group>. 
<article-title>Nf-&#x3ba;b in monocytes and macrophages an inflammatory master regulator in multitalented immune cells</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<elocation-id>1134661</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2023.1134661</pub-id>, PMID: <pub-id pub-id-type="pmid">36911661</pub-id>
</mixed-citation>
</ref>
<ref id="B62">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Porta</surname> <given-names>C</given-names></name>
<name><surname>Rimoldi</surname> <given-names>M</given-names></name>
<name><surname>Raes</surname> <given-names>G</given-names></name>
<name><surname>Brys</surname> <given-names>L</given-names></name>
<name><surname>Ghezzi</surname> <given-names>P</given-names></name>
<name><surname>Liberto</surname> <given-names>DD</given-names></name>
<etal/>
</person-group>. 
<article-title>Tolerance and m2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor b</article-title>. <source>Proc Natl Acad Sci</source>. (<year>2009</year>) <volume>106</volume>:<page-range>14978&#x2013;83</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1073/pnas.0809784106</pub-id>, PMID: <pub-id pub-id-type="pmid">19706447</pub-id>
</mixed-citation>
</ref>
<ref id="B63">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wallach</surname> <given-names>T</given-names></name>
<name><surname>Raden</surname> <given-names>M</given-names></name>
<name><surname>Hinkelmann</surname> <given-names>L</given-names></name>
<name><surname>Brehm</surname> <given-names>M</given-names></name>
<name><surname>Rabsch</surname> <given-names>D</given-names></name>
<name><surname>Weidling</surname> <given-names>H</given-names></name>
<etal/>
</person-group>. 
<article-title>Distinct sars-cov-2 rna fragments activate toll-like receptors 7 and 8 and induce cytokine release from human macrophages and microglia</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>13</volume>:<elocation-id>1066456</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.1066456</pub-id>, PMID: <pub-id pub-id-type="pmid">36713399</pub-id>
</mixed-citation>
</ref>
<ref id="B64">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Chore&#xf1;o-Parra</surname> <given-names>JA</given-names></name>
<name><surname>Jim&#xe9;nez-&#xc1;lvarez</surname> <given-names>LA</given-names></name>
<name><surname>Cruz-Lagunas</surname> <given-names>A</given-names></name>
<name><surname>Rodr&#xed;guez-Reyna</surname> <given-names>TS</given-names></name>
<name><surname>Ram&#xed;rez-Mart&#xed;nez</surname> <given-names>G</given-names></name>
<name><surname>Sandoval-Vega</surname> <given-names>M</given-names></name>
<etal/>
</person-group>. 
<article-title>Clinical and immunological factors that distinguish covid-19 from pandemic influenza a(h1n1)</article-title>. <source>Front Immunol</source>. (<year>2021</year>) <volume>12</volume>:<elocation-id>593595</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2021.593595</pub-id>, PMID: <pub-id pub-id-type="pmid">33995342</pub-id>
</mixed-citation>
</ref>
</ref-list>
<fn-group>
<fn id="n1" fn-type="custom" custom-type="edited-by">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1335553">Xiaocan Guo</ext-link>, Dana-Farber Cancer Institute, United States</p></fn>
<fn id="n2" fn-type="custom" custom-type="reviewed-by">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/596453">Alessandro Palma</ext-link>, Sapienza University of Rome, Italy</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3133929">Ahmed Mobeen</ext-link>, CSIR&#x2019;s Ayurgenomics Unit&#x2013;TRISUTRA (Translational Research and Innovative Science ThRough Ayurgenomics) CSIR-Institute of Genomics and Integrative Biology, India</p></fn>
</fn-group>
</back>
</article>